Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Prostate Cancer

  Free Subscription

Articles published in Prostate

Retrieve available abstracts of 545 articles:
HTML format

Single Articles

    July 2021
    Very low-risk versus low-risk prostate cancer: A distinction worth keeping.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24197.

  2. WEI J, Yang W, Shi Z, Lu L, et al
    Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24195.
    PubMed     Abstract available

  3. FETTKE H, Kwan EM, Bukczynska P, Steen JA, et al
    Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24194.
    PubMed     Abstract available

  4. LIU G, Zhu Y, Yao Z, Jiang Y, et al
    Development and validation of a predictive model for determining clinically significant prostate cancer in men with negative magnetic resonance imaging after transrectal ultrasound-guided prostate biopsy.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24193.
    PubMed     Abstract available

  5. HUANG D, Ruan X, Wu Y, Lin X, et al
    Genetic polymorphisms at 19q13.33 are associated with [-2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24192.
    PubMed     Abstract available

  6. LAUNER BM, Lloyd GL
    Sociodemographic index and global trends in prostate cancer: 1990-2017.
    Prostate. 2021 Jul 5. doi: 10.1002/pros.24178.
    PubMed     Abstract available

  7. CHEN DY, Su PJ, See LC, Liu JR, et al
    Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study.
    Prostate. 2021 Jul 1. doi: 10.1002/pros.24187.
    PubMed     Abstract available

  8. BROGGI G, Lo Giudice A, Di Mauro M, Asmundo MG, et al
    SRSF-1 and microvessel density immunohistochemical analysis by semi-automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study).
    Prostate. 2021 Jul 1. doi: 10.1002/pros.24185.
    PubMed     Abstract available

    June 2021
  9. LV S, Pu X, Luo M, Wen H, et al
    Long noncoding RNA GAS5 interacts and suppresses androgen receptor activity in prostate cancer cells.
    Prostate. 2021 Jun 29. doi: 10.1002/pros.24186.
    PubMed     Abstract available

  10. WENZEL M, Wurnschimmel C, Ruvolo CC, Nocera L, et al
    Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores.
    Prostate. 2021 Jun 29. doi: 10.1002/pros.24184.
    PubMed     Abstract available

  11. LENDINEZ-CANO G, Ojeda-Claro AV, Gomez-Gomez E, Morales Jimenez P, et al
    Prospective study of diagnostic accuracy in the detection of high-grade prostate cancer in biopsy-naive patients with clinical suspicion of prostate cancer who underwent the Select MDx test.
    Prostate. 2021 Jun 29. doi: 10.1002/pros.24182.
    PubMed     Abstract available

  12. BASU HS, Wilganowski N, Robertson S, Reuben JM, et al
    Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities.
    Prostate. 2021 Jun 25. doi: 10.1002/pros.24146.
    PubMed     Abstract available

  13. NUNES-XAVIER CE, Kildal W, Kleppe A, Danielsen HE, et al
    Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
    Prostate. 2021 Jun 14. doi: 10.1002/pros.24180.
    PubMed     Abstract available

  14. WURNSCHIMMEL C, Kachanov M, Wenzel M, Mandel P, et al
    Twenty-year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort.
    Prostate. 2021 Jun 10. doi: 10.1002/pros.24181.
    PubMed     Abstract available

  15. FALEGAN OS, Jarvi K, Vogel HJ, Hyndman ME, et al
    Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7.
    Prostate. 2021 Jun 7. doi: 10.1002/pros.24145.
    PubMed     Abstract available

  16. WANG L, Li H, Li Z, Li M, et al
    Smoothened loss is a characteristic of neuroendocrine prostate cancer.
    Prostate. 2021;81:508-520.
    PubMed     Abstract available

  17. NIZIALEK E, Lim SJ, Wang H, Isaacsson Velho P, et al
    Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
    Prostate. 2021;81:572-579.
    PubMed     Abstract available

    May 2021
  18. LOEB S, Li R, Sanchez Nolasco T, Byrne N, et al
    Barriers and facilitators of germline genetic evaluation for prostate cancer.
    Prostate. 2021 May 31. doi: 10.1002/pros.24172.
    PubMed     Abstract available

  19. QUHAL F, Rajwa P, Mori K, Laukhtina E, et al
    The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer.
    Prostate. 2021 May 31. doi: 10.1002/pros.24173.
    PubMed     Abstract available

  20. SI S, Zheng B, Wang Z, Niu Z, et al
    Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - A retrospective cohort study and meta-analysis.
    Prostate. 2021 May 31. doi: 10.1002/pros.24170.
    PubMed     Abstract available

  21. MISHRA A, Zennami K, Velarde E, Thorek DLJ, et al
    Longitudinal measurement of subcutaneous and intratibial human prostate cancer xenograft growth and response to ionizing radiation by plasma Alu and LINE-1 ctDNA: A comparison to standard methods.
    Prostate. 2021 May 25. doi: 10.1002/pros.24171.
    PubMed     Abstract available

  22. ZHU S, Chen J, Ni Y, Zhang H, et al
    Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients.
    Prostate. 2021 May 24. doi: 10.1002/pros.24167.
    PubMed     Abstract available

  23. WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
    Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy.
    Prostate. 2021 May 19. doi: 10.1002/pros.24169.
    PubMed     Abstract available

  24. FERRARIS F, Yaber F, Smith AB, Barreiro D, et al
    The end of "very low risk" in localized prostate cancer?
    Prostate. 2021 May 19. doi: 10.1002/pros.24168.

  25. SARTOR O, Appukkuttan S, Weiss J, Tsao CK, et al
    Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings.
    Prostate. 2021 May 12. doi: 10.1002/pros.24143.
    PubMed     Abstract available

  26. XU J, Isaacs WB, Mamawala M, Shi Z, et al
    Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients.
    Prostate. 2021 May 6. doi: 10.1002/pros.24140.
    PubMed     Abstract available

  27. BANERJEE M, Li Z, Gao Y, Lai F, et al
    Inverse agonism at the Na/K-ATPase receptor reverses EMT in prostate cancer cells.
    Prostate. 2021 May 6. doi: 10.1002/pros.24144.
    PubMed     Abstract available

  28. WANG V, Geybels MS, Jordahl KM, Gerke T, et al
    A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.
    Prostate. 2021 May 6. doi: 10.1002/pros.24148.
    PubMed     Abstract available

  29. DE GROOT AE, Myers KV, Krueger TEG, Kiemen AL, et al
    Characterization of tumor-associated macrophages in prostate cancer transgenic mouse models.
    Prostate. 2021 May 5. doi: 10.1002/pros.24139.
    PubMed     Abstract available

  30. CHI JT, Lin PH, Tolstikov V, Oyekunle T, et al
    The influence of low-carbohydrate diets on the metabolic response to androgen-deprivation therapy in prostate cancer.
    Prostate. 2021 May 5. doi: 10.1002/pros.24136.
    PubMed     Abstract available

  31. ONAL C, Ozyigit G, Oymak E, Guler OC, et al
    Clinical parameters and nomograms for predicting lymph node metastasis detected with (68) Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy.
    Prostate. 2021 May 5. doi: 10.1002/pros.24142.
    PubMed     Abstract available

    April 2021
  32. TAN B, Chen X, Fan Y, Yang Y, et al
    STAT3 phosphorylation is required for the HepaCAM-mediated inhibition of castration-resistant prostate cancer cell viability and metastasis.
    Prostate. 2021 Apr 28. doi: 10.1002/pros.24141.
    PubMed     Abstract available

  33. BALLAL S, Yadav MP, Sahoo RK, Tripathi M, et al
    (225) Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24137.
    PubMed     Abstract available

  34. QU F, Gu Y, Xue M, He M, et al
    Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24134.
    PubMed     Abstract available

  35. HISHIDA S, Kawakami K, Fujita Y, Kato T, et al
    Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24138.
    PubMed     Abstract available

  36. BOSLAND MC, Nettey OS, Phillips AA, Anunobi CC, et al
    Prevalence of prostate cancer at autopsy in Nigeria-A preliminary report.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24133.
    PubMed     Abstract available

  37. ONAL C, Kose F, Ozyigit G, Aksoy S, et al
    Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24132.
    PubMed     Abstract available

  38. BAZZI LA, Sigurdardottir LG, Sigurdsson S, Valdimarsdottir U, et al
    Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymelatonin levels on prostate cancer risk.
    Prostate. 2021 Apr 16. doi: 10.1002/pros.24130.
    PubMed     Abstract available

  39. THULIN MH, Maatta J, Linder A, Sterbova S, et al
    Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
    Prostate. 2021 Apr 6. doi: 10.1002/pros.24125.
    PubMed     Abstract available

  40. WANG Y, Wu G, Fan L, Pan J, et al
    The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy.
    Prostate. 2021 Apr 6. doi: 10.1002/pros.24126.
    PubMed     Abstract available

  41. LEDET EM, Burgess EF, Sokolova AO, Jaeger EB, et al
    Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
    Prostate. 2021 Apr 1. doi: 10.1002/pros.24123.
    PubMed     Abstract available

    March 2021
  42. SABOL RA, Ledet EM, Jaeger E, Hatton W, et al
    Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
    Prostate. 2021 Mar 24. doi: 10.1002/pros.24120.
    PubMed     Abstract available

  43. CHOI Y, Smith KC, Shukla A, Blackford AL, et al
    What are survivorship care plans failing to tell men after prostate cancer treatment?
    Prostate. 2021 Mar 23. doi: 10.1002/pros.24116.
    PubMed     Abstract available

  44. GRAHAM LS, True LD, Gulati R, Schade GR, et al
    Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
    Prostate. 2021 Mar 23. doi: 10.1002/pros.24118.
    PubMed     Abstract available

  45. LEHTO TK, Sturenberg C, Malen A, Erickson AM, et al
    Transcript analysis of commercial prostate cancer risk stratification panels in hard-to-predict grade group 2-4 prostate cancers.
    Prostate. 2021 Mar 18. doi: 10.1002/pros.24108.
    PubMed     Abstract available

  46. LIOTTI A, La Civita E, Cennamo M, Crocetto F, et al
    Periprostatic adipose tissue promotes prostate cancer resistance to docetaxel by paracrine IGF-1 upregulation of TUBB2B beta-tubulin isoform.
    Prostate. 2021 Mar 18. doi: 10.1002/pros.24117.
    PubMed     Abstract available

  47. ZHENG X, Xu H, Gong L, Cao D, et al
    Vinculin orchestrates prostate cancer progression by regulating tumor cell invasion, migration, and proliferation.
    Prostate. 2021 Mar 12. doi: 10.1002/pros.24113.
    PubMed     Abstract available

  48. ATEEQ B, Kunju LP, Carskadon SL, Pandey SK, et al
    Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.
    Prostate. 2021 Mar 8. doi: 10.1002/pros.24111.

    February 2021
  49. SHENDEROV E, Boudadi K, Fu W, Wang H, et al
    Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial.
    Prostate. 2021 Feb 26. doi: 10.1002/pros.24110.
    PubMed     Abstract available

  50. WETTSTEIN MS, David LA, Pazhepurackel C, Qureshi AA, et al
    Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis.
    Prostate. 2021 Feb 18. doi: 10.1002/pros.24105.
    PubMed     Abstract available

  51. TAO LJ, Pan XY, Wang JW, Zhang L, et al
    Circular RNA circANKS1B acts as a sponge for miR-152-3p and promotes prostate cancer progression by upregulating TGF-alpha expression.
    Prostate. 2021 Feb 8. doi: 10.1002/pros.24102.
    PubMed     Abstract available

  52. LEE JM, Kim U, Yang H, Ryu B, et al
    TALEN-mediated generation of Nkx3.1 knockout rat model.
    Prostate. 2021;81:182-193.
    PubMed     Abstract available

    January 2021
  53. NAITO R, Kano H, Shimada T, Makino T, et al
    A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells.
    Prostate. 2021 Jan 25. doi: 10.1002/pros.24106.
    PubMed     Abstract available

  54. EMAM A, Hermann G, Attwood K, Ji W, et al
    Oncologic outcome of radical prostatectomy versus radiotherapy as primary treatment for high and very high risk localized prostate cancer.
    Prostate. 2021 Jan 20. doi: 10.1002/pros.24089.
    PubMed     Abstract available

  55. VLACHOSTERGIOS PJ, Niaz MJ, Skafida M, Mosallaie SA, et al
    Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted beta-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
    Prostate. 2021 Jan 19. doi: 10.1002/pros.24104.
    PubMed     Abstract available

  56. LIU JM, Lin CC, Chen MF, Liu KL, et al
    Risk of major adverse cardiovascular events among second-line hormonal therapy for metastatic castration-resistant prostate cancer: A real-world evidence study.
    Prostate. 2021 Jan 4. doi: 10.1002/pros.24096.
    PubMed     Abstract available

  57. ZHU Y, Wen J, Huang G, Mittlesteadt J, et al
    CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
    Prostate. 2021;81:81-88.
    PubMed     Abstract available

    December 2020
  58. IMAMURA R, Kitagawa S, Kubo T, Irie A, et al
    Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a.
    Prostate. 2020 Dec 24. doi: 10.1002/pros.24090.
    PubMed     Abstract available

  59. COUGHLIN SS, Vernon M, Klaassen Z, Tingen MS, et al
    Knowledge of prostate cancer among African American men: A systematic review.
    Prostate. 2020 Dec 23. doi: 10.1002/pros.24097.
    PubMed     Abstract available

  60. KAZUNO S, Fujimura T, Fujime M, Miura Y, et al
    O-glycosylated clusterin as a sensitive marker for diagnosing early stages of prostate cancer.
    Prostate. 2020 Dec 21. doi: 10.1002/pros.24094.
    PubMed     Abstract available

  61. ZHANG Y, Mou Y, Liang C, Zhu S, et al
    Promoting cell proliferation, cell cycle progression, and glycolysis: Glycometabolism-related genes act as prognostic signatures for prostate cancer.
    Prostate. 2020 Dec 18. doi: 10.1002/pros.24092.
    PubMed     Abstract available

  62. ZHOU Y, Mai Z, Yan W, Chen Y, et al
    The characteristics and spatial distributions of prostate cancer in autopsy specimens.
    Prostate. 2020 Dec 11. doi: 10.1002/pros.24091.
    PubMed     Abstract available

  63. ZHANG Y, Guo Z, Du T, Chen J, et al
    Prostate specific membrane antigen (PSMA): A novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells.
    Prostate. 2020 Dec 11. doi: 10.1002/pros.24093.

  64. SHEIKHBAHAEI S, Reyes DK, Rowe SP, Pienta KJ, et al
    CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naive oligometastatic prostate cancer.
    Prostate. 2020 Dec 1. doi: 10.1002/pros.24088.
    PubMed     Abstract available

  65. GREENLAND NY, Cowan JE, Chan E, Carroll PR, et al
    Prostate biopsy histopathologic features correlate with a commercial gene expression assay's reclassification of patient NCCN risk category.
    Prostate. 2020;80:1421-1428.
    PubMed     Abstract available

  66. LI W, Bicak M, Sjoberg DD, Vertosick E, et al
    Genome-wide association study identifies novel single nucleotide polymorphisms having age-specific effect on prostate-specific antigen levels.
    Prostate. 2020;80:1405-1412.
    PubMed     Abstract available

    November 2020
  67. SHIH HJ, Fang SC, An L, Shao YJ, et al
    Early-onset prostate cancer is associated with increased risks of disease progression and cancer-specific mortality.
    Prostate. 2020 Nov 5. doi: 10.1002/pros.24087.
    PubMed     Abstract available

  68. YAMOAH K, Lal P, Awasthi S, Naghavi AO, et al
    TMPRSS2-ERG fusion impact anterior tumor location in men with prostate cancer.
    Prostate. 2020 Nov 3. doi: 10.1002/pros.24086.
    PubMed     Abstract available

  69. DEEK M, Lilleby W, Vaage V, Hole KH, et al
    Impact of radiation dose on recurrence in high-risk prostate cancer patients.
    Prostate. 2020;80:1322-1327.
    PubMed     Abstract available

  70. BLACK MH, Li S, LaDuca H, Lo MT, et al
    Validation of a prostate cancer polygenic risk score.
    Prostate. 2020;80:1314-1321.
    PubMed     Abstract available

    October 2020
  71. JARRARD D, Filon M, Huang W, Havighurst T, et al
    A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance.
    Prostate. 2020 Oct 23. doi: 10.1002/pros.24076.
    PubMed     Abstract available

  72. YANG Y, Attwood K, Bshara W, Mohler JL, et al
    High intratumoral CD8(+) T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy.
    Prostate. 2020 Oct 21. doi: 10.1002/pros.24068.
    PubMed     Abstract available

  73. MIYAHIRA AK, Soule HR
    The 26th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Prostate. 2020 Oct 21. doi: 10.1002/pros.24083.
    PubMed     Abstract available

  74. WASHINGTON SL 3RD, Cowan JE, Herlemann A, Zuniga KB, et al
    Influence of pelvic lymph node dissection and node-positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer.
    Prostate. 2020 Oct 19. doi: 10.1002/pros.24085.
    PubMed     Abstract available

  75. AMELOT A, Terrier LM, Le Nail LR, Cristini J, et al
    Spine metastasis in patients with prostate cancer: Survival prognosis assessment.
    Prostate. 2020 Oct 16. doi: 10.1002/pros.24084.
    PubMed     Abstract available

  76. IWAMOTO H, Izumi K, Shimada T, Kano H, et al
    Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer.
    Prostate. 2020 Oct 13. doi: 10.1002/pros.24082.
    PubMed     Abstract available

  77. DING Y, Lee M, Gao Y, Bu P, et al
    Neuropeptide Y nerve paracrine regulation of prostate cancer oncogenesis and therapy resistance.
    Prostate. 2020 Oct 6. doi: 10.1002/pros.24081.
    PubMed     Abstract available

  78. HERTZOG JR, Zhang Z, Bignan G, Connolly PJ, et al
    AKR1C3 mediates pan-AR antagonist resistance in castration-resistant prostate cancer.
    Prostate. 2020;80:1223-1232.
    PubMed     Abstract available

  79. MONTES M, MacKenzie L, McAllister MJ, Roseweir A, et al
    Determining the prognostic significance of IKKalpha in prostate cancer.
    Prostate. 2020;80:1188-1202.
    PubMed     Abstract available

    September 2020
  80. VICIER C, Ravi P, Kwak L, Werner L, et al
    Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer.
    Prostate. 2020 Sep 28. doi: 10.1002/pros.24079.
    PubMed     Abstract available

  81. OMRI N, Kamil M, Alexander K, Alexander K, et al
    Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume.
    Prostate. 2020 Sep 24. doi: 10.1002/pros.24078.
    PubMed     Abstract available

  82. LEE BS, Chu SY, Jung WJ, Jeong HJ, et al
    (18) F-labeled 1,2,3-triazole-linked Glu-urea-Lys-based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer.
    Prostate. 2020 Sep 22. doi: 10.1002/pros.24062.
    PubMed     Abstract available

  83. VILSON FL, Li S, Brooks JD, Eisenberg ML, et al
    Sudden PSA rise to >/=20 ng/ml and prostate cancer diagnosis in the United States: A population-based study.
    Prostate. 2020 Sep 21. doi: 10.1002/pros.24075.
    PubMed     Abstract available

  84. HARSHMAN LC, Wang VX, Hamid AA, Santone G, et al
    Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
    Prostate. 2020 Sep 19. doi: 10.1002/pros.24074.
    PubMed     Abstract available

  85. NAITO Y, Kato M, Kawanishi H, Yuguchi Y, et al
    The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study.
    Prostate. 2020 Sep 11. doi: 10.1002/pros.24069.
    PubMed     Abstract available

  86. DUBEY B, Jackson M, Zeigler-Johnson C, Devarajan K, et al
    Interactive effect of TLR SNPs and exposure to sexually transmitted infections on prostate cancer risk in Jamaican men.
    Prostate. 2020 Sep 7. doi: 10.1002/pros.24067.
    PubMed     Abstract available

  87. ZHANG M, Wang Q, Sun X, Yin Q, et al
    beta2 -adrenergic receptor signaling drives prostate cancer progression by targeting the Sonic hedgehog-Gli1 signaling activation.
    Prostate. 2020 Sep 7. doi: 10.1002/pros.24060.
    PubMed     Abstract available

  88. KAUR H, Samarska I, Lu J, Faisal F, et al
    Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
    Prostate. 2020;80:1012-1023.
    PubMed     Abstract available

  89. ANGEL PM, Spruill L, Jefferson M, Bethard JR, et al
    Zonal regulation of collagen-type proteins and posttranslational modifications in prostatic benign and cancer tissues by imaging mass spectrometry.
    Prostate. 2020;80:1071-1086.
    PubMed     Abstract available

    August 2020
  90. MIYAHIRA AK, Pienta KJ, Babich JW, Bander NH, et al
    Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.
    Prostate. 2020 Aug 31. doi: 10.1002/pros.24056.
    PubMed     Abstract available

  91. MCALLISTER M, Constancio V, Patek S, Gan H, et al
    Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naive prostate cancer.
    Prostate. 2020 Aug 26. doi: 10.1002/pros.24064.
    PubMed     Abstract available

  92. WIGGINS EK, Oyekunle T, Howard LE, Markt SC, et al
    Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trial.
    Prostate. 2020 Aug 24. doi: 10.1002/pros.24052.
    PubMed     Abstract available

  93. LIU W, Hou J, Petkewicz J, Na R, et al
    Feasibility and performance of a novel probe panel to detect somatic DNA copy number alterations in clinical specimens for predicting prostate cancer progression.
    Prostate. 2020 Aug 17. doi: 10.1002/pros.24057.
    PubMed     Abstract available

  94. SHORE ND, Drake CG, Lin DW, Ryan CJ, et al
    Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.
    Prostate. 2020 Aug 11. doi: 10.1002/pros.24053.
    PubMed     Abstract available

  95. DI BELLA CM, Howard LE, Oyekunle T, De Hoedt AM, et al
    Abdominal and pelvic adipose tissue distribution and risk of prostate cancer recurrence after radiation therapy.
    Prostate. 2020 Aug 7. doi: 10.1002/pros.24054.
    PubMed     Abstract available

  96. SIMONS BW, Dalrymple S, Rosen M, Zheng L, et al
    A hemi-spleen injection model of liver metastasis for prostate cancer.
    Prostate. 2020 Aug 6. doi: 10.1002/pros.24055.
    PubMed     Abstract available

  97. NAEEM A, Dakshanamurthy S, Walthieu H, Parasido E, et al
    Predicting new drug indications for prostate cancer: The integration of an in silico proteochemometric network pharmacology platform with patient-derived primary prostate cells.
    Prostate. 2020 Aug 6. doi: 10.1002/pros.24050.
    PubMed     Abstract available

    July 2020
  98. AHMED ME, Andrews JR, Alamiri J, Higa J, et al
    Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes.
    Prostate. 2020 Jul 31. doi: 10.1002/pros.24048.
    PubMed     Abstract available

  99. NANDA JS, Awadallah WN, Kohrt SE, Popovics P, et al
    Increased nuclear factor I/B expression in prostate cancer correlates with AR expression.
    Prostate. 2020 Jul 21. doi: 10.1002/pros.24019.
    PubMed     Abstract available

  100. FERRARI MG, Ganaie AA, Shabenah A, Mansini AP, et al
    Identifying and treating ROBO1(-ve) /DOCK1(+ve) prostate cancer: An aggressive cancer subtype prevalent in African American patients.
    Prostate. 2020 Jul 20. doi: 10.1002/pros.24018.
    PubMed     Abstract available

  101. DEE EC, Nezolosky MD, Chipidza FE, Arega MA, et al
    Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities.
    Prostate. 2020 Jul 13. doi: 10.1002/pros.24041.
    PubMed     Abstract available

  102. ABUDUREXITI M, Zhu W, Wang Y, Wang J, et al
    Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
    Prostate. 2020 Jul 10. doi: 10.1002/pros.24027.
    PubMed     Abstract available

  103. ERICKSON AM, Lokman U, Lahdensuo K, Tornberg S, et al
    PTEN and ERG expression in MRI-ultrasound guided fusion biopsy correlated with radical prostatectomy findings in men with prostate cancer.
    Prostate. 2020 Jul 7. doi: 10.1002/pros.24040.
    PubMed     Abstract available

  104. ZHAN B, Huang L, Chen Y, Ye W, et al
    miR-196a-mediated downregulation of p27(kip1) protein promotes prostate cancer proliferation and relates to biochemical recurrence after radical prostatectomy.
    Prostate. 2020 Jul 6. doi: 10.1002/pros.24036.
    PubMed     Abstract available

  105. FEDERER-GSPONER JR, Muller DC, Zellweger T, Eggimann M, et al
    Patterns of stemness-associated markers in the development of castration-resistant prostate cancer.
    Prostate. 2020 Jul 6. doi: 10.1002/pros.24039.
    PubMed     Abstract available

  106. QIN C, Sheng Z, Huang X, Tang J, et al
    Cancer-driven IgG promotes the development of prostate cancer though the SOX2-CIgG pathway.
    Prostate. 2020 Jul 6. doi: 10.1002/pros.24042.
    PubMed     Abstract available

  107. BONK S, Kluth M, Jansen K, Hube-Magg C, et al
    Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer.
    Prostate. 2020 Jul 6. doi: 10.1002/pros.24038.
    PubMed     Abstract available

  108. TANG M, Gao S, Zhang L, Liu B, et al
    Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
    Prostate. 2020;80:742-752.
    PubMed     Abstract available

  109. RINELLA L, Pizzo B, Frairia R, Delsedime L, et al
    Modulating tumor reactive stroma by extracorporeal shock waves to control prostate cancer progression.
    Prostate. 2020 Jul 1. doi: 10.1002/pros.24037.
    PubMed     Abstract available

    June 2020
  110. CHEN Y, Li X, Mamouni K, Yang Y, et al
    Novel small-molecule LG1836 inhibits the in vivo growth of castration-resistant prostate cancer.
    Prostate. 2020 Jun 19. doi: 10.1002/pros.24032.
    PubMed     Abstract available

  111. MAESHIGE N, Kitagawa K, Yamasaki S, Ishii A, et al
    Can ultrasound irradiation be a therapeutic option for prostate cancer?
    Prostate. 2020 Jun 18. doi: 10.1002/pros.24030.
    PubMed     Abstract available

  112. BEGEMANN D, Wang Y, Yang W, Kyprianou N, et al
    Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
    Prostate. 2020 Jun 16. doi: 10.1002/pros.24015.
    PubMed     Abstract available

  113. WANG K, Chen Z, Shi J, Feng Y, et al
    Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells.
    Prostate. 2020 Jun 15. doi: 10.1002/pros.24029.
    PubMed     Abstract available

  114. TAYLOR RA, Farrelly SG, Clark AK, Watt MJ, et al
    Early intervention exercise training does not delay prostate cancer progression in Pten(-/-) mice.
    Prostate. 2020 Jun 10. doi: 10.1002/pros.24024.
    PubMed     Abstract available

  115. ELHODAKY M, Hong LK, Kadkol S, Diamond AM, et al
    Selenium-binding protein 1 alters energy metabolism in prostate cancer cells.
    Prostate. 2020 Jun 8. doi: 10.1002/pros.24028.
    PubMed     Abstract available

  116. CHADID S, Barber JR, Nelson WG, Gurel B, et al
    The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial.
    Prostate. 2020 Jun 7. doi: 10.1002/pros.24023.
    PubMed     Abstract available

  117. CARSON JJK, Di Lena MA, Berman DM, Siemens DR, et al
    Development and initial clinical correlation of a DNA methylation-based blood test for prostate cancer.
    Prostate. 2020 Jun 7. doi: 10.1002/pros.24025.
    PubMed     Abstract available

  118. RII J, Sakamoto S, Yamada Y, Takeshita N, et al
    Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients.
    Prostate. 2020 Jun 5. doi: 10.1002/pros.24016.
    PubMed     Abstract available

  119. CHEN X, Chen F, Ren Y, Weng G, et al
    Glucocorticoid receptor upregulation increases radioresistance and triggers androgen independence of prostate cancer.
    Prostate. 2020;80:727.

  120. OJALILL M, Virtanen N, Rappu P, Siljamaki E, et al
    Interaction between prostate cancer cells and prostate fibroblasts promotes accumulation and proteolytic processing of basement membrane proteins.
    Prostate. 2020;80:715-726.
    PubMed     Abstract available

  121. ITSUMI M, Shiota M, Sekino Y, Ushijima M, et al
    High-throughput screen identifies 5-HT receptor as a modulator of AR and a therapeutic target for prostate cancer.
    Prostate. 2020 Jun 1. doi: 10.1002/pros.24022.
    PubMed     Abstract available

  122. ELSHAFAE SM, Dirksen WP, Alasonyalilar-Demirer A, Breitbach J, et al
    Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.
    Prostate. 2020;80:698-714.
    PubMed     Abstract available

  123. PALANGMONTHIP W, Wu R, Tarima S, Bobholz SA, et al
    Corpora amylacea in benign prostatic acini are associated with concurrent, predominantly low-grade cancer.
    Prostate. 2020;80:687-697.
    PubMed     Abstract available

    May 2020
  124. LINDER A, Larsson K, Welen K, Damber JE, et al
    RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Prostate. 2020 May 25. doi: 10.1002/pros.23994.
    PubMed     Abstract available

  125. TABEI T, Taguri M, Sakai N, Koh H, et al
    Does screening for prostate cancer improve cancer-specific mortality in Asian men? Real-world data in Yokosuka City 15 years after introducing PSA-based population screening.
    Prostate. 2020 May 20. doi: 10.1002/pros.23997.
    PubMed     Abstract available

  126. SHI X, Sun J, Li H, Lin H, et al
    Antitumor efficacy of interferon-gamma-modified exosomal vaccine in prostate cancer.
    Prostate. 2020 May 19. doi: 10.1002/pros.23996.
    PubMed     Abstract available

  127. HOU Y, Li H, Huo W
    THBS4 silencing regulates the cancer stem cell-like properties in prostate cancer via blocking the PI3K/Akt pathway.
    Prostate. 2020 May 18. doi: 10.1002/pros.23989.
    PubMed     Abstract available

  128. LIU Z, Murphy SF, Huang J, Zhao L, et al
    A novel immunocompetent model of metastatic prostate cancer-induced bone pain.
    Prostate. 2020 May 14. doi: 10.1002/pros.23993.
    PubMed     Abstract available

  129. LUNDGREN PO, Kjellman A, Norming U, Gustafsson O, et al
    Association between dihydrotestosterone and long-term risk for prostate cancer mortality: A prospective cohort study.
    Prostate. 2020 May 5. doi: 10.1002/pros.23991.
    PubMed     Abstract available

  130. LIU S, Liu F, Zhang B, Yan P, et al
    CD4(+) T helper 17 cell response of aged mice promotes prostate cancer cell migration and invasion.
    Prostate. 2020 May 1. doi: 10.1002/pros.23990.
    PubMed     Abstract available

  131. SU X, Long Q, Bo J, Shi Y, et al
    Mutational and transcriptomic landscapes of a rare human prostate basal cell carcinoma.
    Prostate. 2020;80:508-517.
    PubMed     Abstract available

  132. GLEAVE AM, Ci X, Lin D, Wang Y, et al
    A synopsis of prostate organoid methodologies, applications, and limitations.
    Prostate. 2020;80:518-526.
    PubMed     Abstract available

  133. GREENLAND NY, Cowan JE, Zhang L, Carroll PR, et al
    Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4.
    Prostate. 2020;80:653-659.
    PubMed     Abstract available

    April 2020
  134. SEBBEN M, Tafuri A, Porcaro AB, Artibani W, et al
    Response to: Bando et al. Diagnostic and therapeutic value of pelvic lymph node dissection in the fossa of Marcille in patients with clinically localized high-risk prostate cancer: Histological and molecular analyses.
    Prostate. 2020 Apr 23. doi: 10.1002/pros.23987.

  135. LI X, Jiao M, Hu J, Qi M, et al
    miR-30a inhibits androgen-independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4.
    Prostate. 2020 Apr 15. doi: 10.1002/pros.23979.
    PubMed     Abstract available

  136. CHENG Y, Wang D, Jiang J, Huang W, et al
    Integrative analysis of AR-mediated transcriptional regulatory network reveals IRF1 as an inhibitor of prostate cancer progression.
    Prostate. 2020 Apr 13. doi: 10.1002/pros.23976.
    PubMed     Abstract available

    March 2020
  137. CARIGNAN D, Lessard T, Villeneuve L, Desjardins S, et al
    DNA repair gene polymorphisms, tumor control, and treatment toxicity in prostate cancer patients treated with permanent implant prostate brachytherapy.
    Prostate. 2020 Mar 23. doi: 10.1002/pros.23975.
    PubMed     Abstract available

  138. DERLIN T, Sommerlath Sohns JM, Schmuck S, Henkenberens C, et al
    Influence of short-term dexamethasone on the efficacy of (177) Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
    Prostate. 2020 Mar 18. doi: 10.1002/pros.23974.
    PubMed     Abstract available

  139. LIU W, Zhang Y, Wei S, Bae S, et al
    A CD24-p53 axis contributes to African American prostate cancer disparities.
    Prostate. 2020 Mar 13. doi: 10.1002/pros.23973.
    PubMed     Abstract available

  140. ZHANG J, Kim S, Li L, Kemp CJ, et al
    Proteomic and transcriptomic profiling of Pten gene-knockout mouse model of prostate cancer.
    Prostate. 2020 Mar 12. doi: 10.1002/pros.23972.
    PubMed     Abstract available

  141. CONNELL SP, O'Reilly E, Tuzova A, Webb M, et al
    Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer.
    Prostate. 2020 Mar 9. doi: 10.1002/pros.23968.
    PubMed     Abstract available

  142. SEO HK, Lee SJ, Kwon WA, Jeong KC, et al
    Docetaxel-resistant prostate cancer cells become sensitive to gemcitabine due to the upregulation of ABCB1.
    Prostate. 2020 Mar 5. doi: 10.1002/pros.23946.
    PubMed     Abstract available

  143. YAMADA Y, Sakamoto S, Rii J, Yamamoto S, et al
    Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer.
    Prostate. 2020 Mar 5. doi: 10.1002/pros.23969.
    PubMed     Abstract available

  144. SHORE ND, Antonarakis ES, Cookson MS, Crawford ED, et al
    Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.
    Prostate. 2020 Mar 4. doi: 10.1002/pros.23967.
    PubMed     Abstract available

  145. LEU WJ, Wang CT, Hsu JL, Chen IS, et al
    Ascleposide, a natural cardenolide, induces anticancer signaling in human castration-resistant prostatic cancer through Na(+) /K(+) -ATPase internalization and tubulin acetylation.
    Prostate. 2020;80:305-318.
    PubMed     Abstract available

  146. WU Z, Wang K, Yang Z, Pascal LE, et al
    A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR(F876L) nuclear import and function.
    Prostate. 2020;80:319-328.
    PubMed     Abstract available

    February 2020
  147. RUBIO-BRIONES J, Borque-Fernando A, Esteban LM, Mascaros JM, et al
    Validation of a 2-gene mRNA urine test for the detection of >/=GG2 prostate cancer in an opportunistic screening population.
    Prostate. 2020 Feb 20. doi: 10.1002/pros.23964.
    PubMed     Abstract available

  148. BRADY L, Gil da Costa RM, Coleman IM, Matson CK, et al
    A comparison of prostate cancer cell transcriptomes in 2D monoculture vs 3D xenografts identify consistent gene expression alterations associated with tumor microenvironments.
    Prostate. 2020 Feb 18. doi: 10.1002/pros.23963.
    PubMed     Abstract available

  149. MARLIN R, Creoff M, Merle S, Jean-Marie-Flore M, et al
    Mutation HOXB13 c.853delT in Martinican prostate cancer patients.
    Prostate. 2020 Feb 10. doi: 10.1002/pros.23960.
    PubMed     Abstract available

  150. GREENBERG S, Slager S, Neil BO, Cooney K, et al
    What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing.
    Prostate. 2020 Feb 6. doi: 10.1002/pros.23959.
    PubMed     Abstract available

  151. YAMADA Y, Sakamoto S, Rii J, Yamamoto S, et al
    How many bone metastases may be defined as high-volume metastatic prostate cancer in Asians: A retrospective multicenter cohort study.
    Prostate. 2020 Feb 3. doi: 10.1002/pros.23958.
    PubMed     Abstract available

  152. YEON A, Wang Y, Su S, Lo EM, et al
    Syngeneic murine model for prostate cancer using RM1 cells transfected with gp100.
    Prostate. 2020 Feb 3. doi: 10.1002/pros.23957.
    PubMed     Abstract available

  153. ERDEM S, Verep S, Bagbudar S, Ozluk Y, et al
    The clinical predictive factors and postoperative histopathological parameters associated with upgrading after radical prostatectomy: A contemporary analysis with grade groups.
    Prostate. 2020;80:225-234.
    PubMed     Abstract available

  154. FAGERLAND ST, Hill DK, van Wamel A, de Lange Davies C, et al
    Ultrasound and magnetic resonance imaging for group stratification and treatment monitoring in the transgenic adenocarcinoma of the mouse prostate model.
    Prostate. 2020;80:186-197.
    PubMed     Abstract available

  155. TAYLOR AS, Morgan TM, Wallington DG, Chinnaiyan AM, et al
    Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier.
    Prostate. 2020;80:146-152.
    PubMed     Abstract available

  156. THOMAS-JARDIN SE, Dahl H, Kanchwala MS, Ha F, et al
    RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
    Prostate. 2020;80:133-145.
    PubMed     Abstract available

  157. WANG R, Lewis MS, Lyu J, Zhau HE, et al
    Cancer-stromal cell fusion as revealed by fluorescence protein tracking.
    Prostate. 2020;80:274-283.
    PubMed     Abstract available

    January 2020
  158. VENUGOPAL SV, Caggia S, Gambrell-Sanders D, Khan SA, et al
    Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells.
    Prostate. 2020 Jan 29. doi: 10.1002/pros.23956.
    PubMed     Abstract available

  159. MARKOWSKI MC, Shenderov E, Eisenberger MA, Kachhap S, et al
    Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.
    Prostate. 2020 Jan 23. doi: 10.1002/pros.23955.
    PubMed     Abstract available

  160. XING Z, Li S, Liu Z, Zhang C, et al
    CTCF-induced upregulation of HOXA11-AS facilitates cell proliferation and migration by targeting miR-518b/ACTN4 axis in prostate cancer.
    Prostate. 2020 Jan 23. doi: 10.1002/pros.23953.
    PubMed     Abstract available

  161. WENJING H, Shao Y, Yu Y, Huang W, et al
    Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation.
    Prostate. 2020 Jan 22. doi: 10.1002/pros.23951.
    PubMed     Abstract available

  162. LI X, Huang H, Zhang J, Jiang F, et al
    A qualitative transcriptional signature for predicting the biochemical recurrence risk of prostate cancer patients after radical prostatectomy.
    Prostate. 2020 Jan 21. doi: 10.1002/pros.23952.
    PubMed     Abstract available

  163. ANDREWS JR, Ahmed ME, Karnes RJ, Kwon E, et al
    Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
    Prostate. 2020 Jan 13. doi: 10.1002/pros.23954.
    PubMed     Abstract available

  164. SONG Q, Qin S, Pascal LE, Zou C, et al
    SIRPB1 promotes prostate cancer cell proliferation via Akt activation.
    Prostate. 2020 Jan 6. doi: 10.1002/pros.23950.
    PubMed     Abstract available

  165. HAWLEY JE, Pan S, Figg WD, Lopez-Bujanda ZA, et al
    Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy.
    Prostate. 2020 Jan 3. doi: 10.1002/pros.23948.
    PubMed     Abstract available

  166. BANDO Y, Hinata N, Terakawa T, Furukawa J, et al
    Diagnostic and therapeutic value of pelvic lymph node dissection in the fossa of Marcille in patients with clinically localized high-risk prostate cancer: Histopathological and molecular analyses.
    Prostate. 2020 Jan 3. doi: 10.1002/pros.23949.
    PubMed     Abstract available

    December 2019
  167. HOSSAIN A, Arimura H, Kinoshita F, Ninomiya K, et al
    Automated approach for estimation of grade groups for prostate cancer based on histological image feature analysis.
    Prostate. 2019 Dec 23. doi: 10.1002/pros.23943.
    PubMed     Abstract available

  168. MOLLARD P, Perrot E, Blanchet P, Brureau L, et al
    Overall, specific, and metastasis-free survival of Afro-Caribbean men with pathological Gleason 6 prostate cancer.
    Prostate. 2019 Dec 23. doi: 10.1002/pros.23947.
    PubMed     Abstract available

  169. KATO M, Hirakawa A, Kobayashi Y, Yamamoto A, et al
    Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients.
    Prostate. 2019 Dec 20. doi: 10.1002/pros.23942.
    PubMed     Abstract available

  170. CHEN X, Liu J, Cheng L, Li C, et al
    Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Prostate. 2019 Dec 19. doi: 10.1002/pros.23939.
    PubMed     Abstract available

  171. GRUBER M, Handle F, Culig Z
    The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells.
    Prostate. 2019 Dec 13. doi: 10.1002/pros.23940.
    PubMed     Abstract available

  172. MIYAHIRA AK, Sharp A, Ellis L, Jones J, et al
    Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.
    Prostate. 2019 Dec 11. doi: 10.1002/pros.23934.
    PubMed     Abstract available

  173. ANDO K, Sakamoto S, Takeshita N, Fujimoto A, et al
    Higher serum testosterone levels predict poor prognosis in castration-resistant prostate cancer patients treated with docetaxel.
    Prostate. 2019 Dec 9. doi: 10.1002/pros.23938.
    PubMed     Abstract available

  174. YLITALO EB, Thysell E, Thellenberg-Karlsson C, Lundholm M, et al
    Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
    Prostate. 2019 Dec 4. doi: 10.1002/pros.23935.
    PubMed     Abstract available

  175. PARDY L, Rosati R, Soave C, Huang Y, et al
    The ternary complex factor protein ELK1 is an independent prognosticator of disease recurrence in prostate cancer.
    Prostate. 2019 Dec 3. doi: 10.1002/pros.23932.
    PubMed     Abstract available

  176. FERNANDEZ-CONEJO G, Hernandez V, Guijarro A, de la Pena E, et al
    Prostate cancer adverse pathology reclassification in patients undergoing active surveillance in a long-term follow-up series.
    Prostate. 2019 Dec 2. doi: 10.1002/pros.23933.
    PubMed     Abstract available

    November 2019
  177. ELIX CC, Salgia MM, Otto-Duessel M, Copeland BT, et al
    Peroxisome proliferator-activated receptor gamma controls prostate cancer cell growth through AR-dependent and independent mechanisms.
    Prostate. 2019 Nov 26. doi: 10.1002/pros.23928.
    PubMed     Abstract available

  178. VICKMAN RE, Broman MM, Lanman NA, Franco OE, et al
    Heterogeneity of human prostate carcinoma-associated fibroblasts implicates a role for subpopulations in myeloid cell recruitment.
    Prostate. 2019 Nov 25. doi: 10.1002/pros.23929.
    PubMed     Abstract available

  179. PETRYLAK DP, Vogelzang NJ, Chatta K, Fleming MT, et al
    PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
    Prostate. 2019 Nov 19. doi: 10.1002/pros.23922.
    PubMed     Abstract available

  180. BADAL S, Aiken W, Morrison B, Valentine H, et al
    Disparities in prostate cancer incidence and mortality rates: Solvable or not?
    Prostate. 2019 Nov 8. doi: 10.1002/pros.23923.
    PubMed     Abstract available

  181. LEDET EM, Antonarakis ES, Isaacs WB, Lotan TL, et al
    Germline BLM mutations and metastatic prostate cancer.
    Prostate. 2019 Nov 5. doi: 10.1002/pros.23924.
    PubMed     Abstract available

  182. FENG Y, Jaratlerdsiri W, Patrick SM, Lyons RJ, et al
    Metagenomic analysis reveals a rich bacterial content in high-risk prostate tumors from African men.
    Prostate. 2019;79:1731-1738.
    PubMed     Abstract available

    October 2019
  183. KIM M, Kim JK, Ye C, Lee H, et al
    Clinical and pathologic characteristics of familial prostate cancer in Asian population.
    Prostate. 2019 Oct 30. doi: 10.1002/pros.23917.
    PubMed     Abstract available

  184. CARBONETTI G, Converso C, Clement T, Wang C, et al
    Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
    Prostate. 2019 Oct 29. doi: 10.1002/pros.23921.
    PubMed     Abstract available

  185. YU H, Shi Z, Lin X, Bao Q, et al
    Broad- and narrow-sense validity performance of three polygenic risk score methods for prostate cancer risk assessment.
    Prostate. 2019 Oct 21. doi: 10.1002/pros.23920.
    PubMed     Abstract available

  186. SHAO L, Kahraman N, Yan G, Wang J, et al
    Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer.
    Prostate. 2019 Oct 15. doi: 10.1002/pros.23918.
    PubMed     Abstract available

  187. GRUBMULLER B, Rasul S, Baltzer P, Fajkovic H, et al
    Response assessment using [(68) Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer.
    Prostate. 2019 Oct 15. doi: 10.1002/pros.23919.
    PubMed     Abstract available

  188. ASSEL MJ, Ulmert HD, Karnes RJ, Boorjian SA, et al
    Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men.
    Prostate. 2019 Oct 11. doi: 10.1002/pros.23916.
    PubMed     Abstract available

  189. LU Z, Williamson SR, Carskadon S, Arachchige PD, et al
    Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.
    Prostate. 2019 Oct 4. doi: 10.1002/pros.23914.
    PubMed     Abstract available

  190. YORDANOVA A, Linden P, Hauser S, Feldmann G, et al
    The value of tumor markers in men with metastatic prostate cancer undergoing [(177) Lu]Lu-PSMA therapy.
    Prostate. 2019 Oct 3. doi: 10.1002/pros.23912.
    PubMed     Abstract available

  191. CACKOWSKI FC, Wang Y, Decker JT, Sifuentes C, et al
    Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer.
    Prostate. 2019;79:1715-1727.
    PubMed     Abstract available

  192. UZUN H, Arpa M
    The impact of diurnal variation of PSA on timing of measurement in prostate biopsy.
    Prostate. 2019;79:1666-1672.
    PubMed     Abstract available

    September 2019
  193. KVALE R, Myklebust TA, Fossa SD, Aas K, et al
    Impact of positive surgical margins on secondary treatment, palliative radiotherapy and prostate cancer-specific mortality. A population-based study of 13 198 patients.
    Prostate. 2019 Sep 30. doi: 10.1002/pros.23911.
    PubMed     Abstract available

  194. PREISSER F, Coxilha G, Heinze A, Oh S, et al
    Impact of positive surgical margin length and Gleason grade at the margin on biochemical recurrence in patients with organ-confined prostate cancer.
    Prostate. 2019 Sep 25. doi: 10.1002/pros.23908.
    PubMed     Abstract available

  195. LOW JY, Sirajuddin P, Moubarek M, Agarwal S, et al
    Effective targeting of RNA polymerase I in treatment-resistant prostate cancer.
    Prostate. 2019 Sep 16. doi: 10.1002/pros.23909.
    PubMed     Abstract available

  196. ZHU Z, Hong Y, Zhang F, An L, et al
    Knockdown of COPS3 inhibits the progress of prostate cancer through reducing phosphorylated p38 MAPK expression and impairs the epithelial-mesenchymal transition process.
    Prostate. 2019 Sep 11. doi: 10.1002/pros.23907.
    PubMed     Abstract available

  197. VELLKY JE, Bauman TM, Ricke EA, Huang W, et al
    Incidence of androgen receptor and androgen receptor variant 7 coexpression in prostate cancer.
    Prostate. 2019 Sep 10. doi: 10.1002/pros.23906.
    PubMed     Abstract available

  198. ROBERTO D, Selvarajah S, Park PC, Berman D, et al
    Functional validation of metabolic genes that distinguish Gleason 3 from Gleason 4 prostate cancer foci.
    Prostate. 2019 Sep 10. doi: 10.1002/pros.23903.
    PubMed     Abstract available

  199. GEORGE DJ, Halabi S, Healy P, Barak I, et al
    Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
    Prostate. 2019 Sep 9. doi: 10.1002/pros.23899.
    PubMed     Abstract available

  200. XU Y, Huang D, Wu Y, Ye D, et al
    Family history is significantly associated with prostate cancer and its early onset in Chinese population.
    Prostate. 2019 Sep 9. doi: 10.1002/pros.23900.
    PubMed     Abstract available

  201. JANG WS, Koh DH, Kim J, Lee JS, et al
    The prognostic impact of downgrading and upgrading from biopsy to radical prostatectomy among men with Gleason score 7 prostate cancer.
    Prostate. 2019 Sep 4. doi: 10.1002/pros.23905.
    PubMed     Abstract available

  202. PERROUIN-VERBE MA, Schoentgen N, Talagas M, Garlantezec R, et al
    Overexpression of certain transient receptor potential and Orai channels in prostate cancer is associated with decreased risk of systemic recurrence after radical prostatectomy.
    Prostate. 2019 Sep 2. doi: 10.1002/pros.23904.
    PubMed     Abstract available

  203. JONCAS FH, Lucien F, Rouleau M, Morin F, et al
    Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients.
    Prostate. 2019 Sep 2. doi: 10.1002/pros.23901.
    PubMed     Abstract available

  204. FU S, Wan X, Du C, Wang H, et al
    A novel fluorescent probe for the early detection of prostate cancer based on endogenous zinc sensing.
    Prostate. 2019;79:1378-1385.
    PubMed     Abstract available

  205. ROUSSEAU C, Le Thiec M, Ferrer L, Rusu D, et al
    Preliminary results of a (68) Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making.
    Prostate. 2019;79:1514-1522.
    PubMed     Abstract available

  206. MIYAZAWA Y, Sekine Y, Shimizu N, Takezawa Y, et al
    An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression.
    Prostate. 2019;79:1462-1470.
    PubMed     Abstract available

  207. METZGER AL, Abel S, Wegner RE, Fuhrer R, et al
    Patterns of care and outcomes in small cell carcinoma of the prostate: A national cancer database analysis.
    Prostate. 2019;79:1457-1461.
    PubMed     Abstract available

  208. KRANZBUHLER B, Salemi S, Umbricht CA, Deberle LM, et al
    Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of (177) Lu-PSMA-617 in LNCaP cells.
    Prostate. 2019;79:1450-1456.
    PubMed     Abstract available

  209. AMEND SR, Torga G, Lin KC, Kostecka LG, et al
    Polyploid giant cancer cells: Unrecognized actuators of tumorigenesis, metastasis, and resistance.
    Prostate. 2019;79:1489-1497.
    PubMed     Abstract available

  210. HUANG SY, Huang GJ, Hsieh PF, Wu HC, et al
    Osajin displays potential antiprostate cancer efficacy via impairment of fatty acid synthase and androgen receptor expression.
    Prostate. 2019;79:1543-1552.
    PubMed     Abstract available

    August 2019
  211. SHISHODIA G, Koul S, Koul HK
    Protocadherin 7 is overexpressed in castration resistant prostate cancer and promotes aberrant MEK and AKT signaling.
    Prostate. 2019 Aug 26. doi: 10.1002/pros.23898.
    PubMed     Abstract available

  212. SARTOR O, Heinrich D, Mariados N, Mendez Vidal MJ, et al
    Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
    Prostate. 2019 Aug 23. doi: 10.1002/pros.23893.
    PubMed     Abstract available

  213. PATEL PG, Wessel T, Kawashima A, Okello JBA, et al
    A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer.
    Prostate. 2019 Aug 21. doi: 10.1002/pros.23895.
    PubMed     Abstract available

  214. WU T, Zhao J, Liu Z, Shen P, et al
    Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?
    Prostate. 2019 Aug 21. doi: 10.1002/pros.23892.
    PubMed     Abstract available

  215. MADUEKE I, Hu WY, Hu D, Swanson SM, et al
    The role of WNT10B in normal prostate gland development and prostate cancer.
    Prostate. 2019 Aug 21. doi: 10.1002/pros.23894.
    PubMed     Abstract available

  216. ZHAO C, Zhang W, Zhu X, Xu Y, et al
    TWIST2: A new candidate tumor suppressor in prostate cancer.
    Prostate. 2019 Aug 21. doi: 10.1002/pros.23889.
    PubMed     Abstract available

  217. WATANABE M, Kanao K, Suzuki S, Muramatsu H, et al
    Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis.
    Prostate. 2019 Aug 7. doi: 10.1002/pros.23890.
    PubMed     Abstract available

  218. SHENDEROV E, Isaacsson Velho P, Awan AH, Wang H, et al
    Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype.
    Prostate. 2019 Aug 7. doi: 10.1002/pros.23881.
    PubMed     Abstract available

  219. MEUNIER ME, Tantot J, Neuzillet Y, Ghoneim TP, et al
    Grade groups at diagnosis in African Caribbean men with prostate cancer: Results of a comparative study.
    Prostate. 2019 Aug 2. doi: 10.1002/pros.23888.
    PubMed     Abstract available

  220. KAIPAINEN A, Zhang A, Gil da Costa RM, Lucas J, et al
    Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion.
    Prostate. 2019 Aug 2. doi: 10.1002/pros.23874.
    PubMed     Abstract available

  221. EICH ML, Chandrashekar DS, Rodriguez Pen A MDC, Robinson AD, et al
    Characterization of glycine-N-acyltransferase like 1 (GLYATL1) in prostate cancer.
    Prostate. 2019 Aug 2. doi: 10.1002/pros.23887.
    PubMed     Abstract available

  222. WANG J, Xu W, Mierxiati A, Huang Y, et al
    Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
    Prostate. 2019 Aug 2. doi: 10.1002/pros.23878.
    PubMed     Abstract available

  223. TANAKA M, Kimura T, Iwamura Y, Enei Y, et al
    No survival benefit found after extended treatment with docetaxel for patients with castration-resistant prostate cancer.
    Prostate. 2019 Aug 2. doi: 10.1002/pros.23884.
    PubMed     Abstract available

  224. CHENG A, Zhao S, FitzGerald LM, Wright JL, et al
    A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies.
    Prostate. 2019 Aug 2. doi: 10.1002/pros.23882.
    PubMed     Abstract available

  225. PILLING AB, Hwang C
    Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide.
    Prostate. 2019;79:1347-1359.
    PubMed     Abstract available

  226. YANG T, An Z, Zhang C, Wang Z, et al
    hnRNPM, a potential mediator of YY1 in promoting the epithelial-mesenchymal transition of prostate cancer cells.
    Prostate. 2019;79:1199-1210.
    PubMed     Abstract available

  227. LOLLI C, De Lisi D, Conteduca V, Gurioli G, et al
    Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Prostate. 2019;79:1211-1220.
    PubMed     Abstract available

  228. PEIFFER LB, Poynton SL, Ernst SE, Hicks JL, et al
    Inflammation-associated pathologies in a case of prostate schistosomiasis: Implications for a causal role in prostate carcinogenesis.
    Prostate. 2019;79:1316-1325.
    PubMed     Abstract available

  229. DONG F, Yang P, Wang R, Sun W, et al
    Triptonide acts as a novel antiprostate cancer agent mainly through inhibition of mTOR signaling pathway.
    Prostate. 2019;79:1284-1293.
    PubMed     Abstract available

  230. YANG J, Broman MM, Cooper PO, Lanman NA, et al
    Distinct expression patterns of SULT2B1b in human prostate epithelium.
    Prostate. 2019;79:1256-1266.
    PubMed     Abstract available

  231. SHAH RB, Shore KT, Yoon J, Mendrinos S, et al
    PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).
    Prostate. 2019;79:1267-1273.
    PubMed     Abstract available

    July 2019
  232. PALLER CJ, Piana D, Eshleman JR, Riel S, et al
    A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
    Prostate. 2019 Jul 30. doi: 10.1002/pros.23883.
    PubMed     Abstract available

  233. HELLSTEN R, Lilljebjorn L, Johansson M, Leandersson K, et al
    The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors.
    Prostate. 2019 Jul 26. doi: 10.1002/pros.23885.
    PubMed     Abstract available

  234. SILVESTRI R, Pucci P, Venalainen E, Matheou C, et al
    T-type calcium channels drive the proliferation of androgen-receptor negative prostate cancer cells.
    Prostate. 2019 Jul 23. doi: 10.1002/pros.23879.
    PubMed     Abstract available

  235. CHEN X, Chen F, Ren Y, Weng G, et al
    Glucocorticoid receptor upregulation increases radioresistance and triggers androgen independence of prostate cancer.
    Prostate. 2019 Jul 23. doi: 10.1002/pros.23861.
    PubMed     Abstract available

  236. MIYAHIRA AK, Soule HR
    The 25th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Prostate. 2019 Jul 23. doi: 10.1002/pros.23872.
    PubMed     Abstract available

  237. KAWADA T
    RE: Joentausta et al. Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. Prostate. 2019;79:583-591.
    Prostate. 2019 Jul 23. doi: 10.1002/pros.23862.

  238. ZHAO J, Zhang M, Liu J, Liu Z, et al
    AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
    Prostate. 2019 Jul 11. doi: 10.1002/pros.23875.
    PubMed     Abstract available

  239. NAM RK, Benatar T, Wallis CJD, Kobylecky E, et al
    MicroRNA-139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL.
    Prostate. 2019 Jul 3. doi: 10.1002/pros.23871.
    PubMed     Abstract available

  240. VEREP S, Erdem S, Ozluk Y, Kilicaslan I, et al
    The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?
    Prostate. 2019 Jul 3. doi: 10.1002/pros.23873.
    PubMed     Abstract available

  241. BLOM S, Erickson A, Ostman A, Rannikko A, et al
    Fibroblast as a critical stromal cell type determining prognosis in prostate cancer.
    Prostate. 2019 Jul 3. doi: 10.1002/pros.23867.
    PubMed     Abstract available

  242. WANG D, Wan X, Zhang Y, Kong Z, et al
    A novel androgen-reduced prostate-specific lncRNA, PSLNR, inhibits prostate-cancer progression in part by regulating the p53-dependent pathway.
    Prostate. 2019 Jul 3. doi: 10.1002/pros.23840.
    PubMed     Abstract available

  243. HU WY, Xu L, Chen B, Ou S, et al
    Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75.
    Prostate. 2019;79:1166-1179.
    PubMed     Abstract available

  244. SHIOTA M, Ushijima M, Imada K, Kashiwagi E, et al
    Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy.
    Prostate. 2019;79:1147-1155.
    PubMed     Abstract available

  245. ROGERS O, Yen H, Solomon A, Drake C, et al
    An IL-2 proaerolysin fusion toxin that selectively eliminates regulatory t cells to enhance antitumor immune response.
    Prostate. 2019;79:1071-1078.
    PubMed     Abstract available

  246. YU H, Shi Z, Wu Y, Wang CH, et al
    Concept and benchmarks for assessing narrow-sense validity of genetic risk score values.
    Prostate. 2019;79:1099-1105.
    PubMed     Abstract available

  247. KATO M, Hirakawa A, Kobayashi Y Ms, Yamamoto A, et al
    The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance.
    Prostate. 2019;79:1065-1070.
    PubMed     Abstract available

    June 2019
  248. JOENTAUSTA RM, Murtola TJ
    Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. Prostate. 2019;79:583-591.
    Prostate. 2019 Jun 24. doi: 10.1002/pros.23870.

  249. KNUUTTILA E, Riikonen J, Syvala H, Auriola S, et al
    Access and concentrations of atorvastatin in the prostate in men with prostate cancer.
    Prostate. 2019 Jun 24. doi: 10.1002/pros.23863.
    PubMed     Abstract available

  250. UGGE H, Downer MK, Carlsson J, Bowden M, et al
    Circulating inflammation markers and prostate cancer.
    Prostate. 2019 Jun 18. doi: 10.1002/pros.23842.
    PubMed     Abstract available

  251. LEE MS, Lee J, Kim YM, Lee H, et al
    The metastasis suppressor CD82/KAI1 represses the TGF-beta 1 and Wnt signalings inducing epithelial-to-mesenchymal transition linked to invasiveness of prostate cancer cells.
    Prostate. 2019 Jun 18. doi: 10.1002/pros.23837.
    PubMed     Abstract available

  252. PORTER LH, Lawrence MG, Wang H, Clark AK, et al
    Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer.
    Prostate. 2019 Jun 18. doi: 10.1002/pros.23839.
    PubMed     Abstract available

  253. YU W, Li J, Wang Q, Wang B, et al
    Targeting POH1 inhibits prostate cancer cell growth and enhances the suppressive efficacy of androgen deprivation and docetaxel.
    Prostate. 2019 Jun 18. doi: 10.1002/pros.23838.
    PubMed     Abstract available

  254. TEPLY BA, Qiu F, Antonarakis ES, Carducci MA, et al
    Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302.
    Prostate. 2019;79:929-933.
    PubMed     Abstract available

  255. BAUMANN B, Lugli G, Gao S, Zenner M, et al
    High levels of PIWI-interacting RNAs are present in the small RNA landscape of prostate epithelium from vitamin D clinical trial specimens.
    Prostate. 2019;79:840-855.
    PubMed     Abstract available

  256. KIM S, Yang X, Yin A, Zha J, et al
    Dietary palmitate cooperates with Src kinase to promote prostate tumor progression.
    Prostate. 2019;79:896-908.
    PubMed     Abstract available

  257. ZHANG P, Lu Y, Kong Z, Zhang Y, et al
    Androgen-responsive lncRNA LINC00304 promotes cell cycle and proliferation via regulating CCNA1.
    Prostate. 2019;79:994-1006.
    PubMed     Abstract available

  258. AARON-BROOKS LM, Sasaki T, Vickman RE, Wei L, et al
    Hyperglycemia and T Cell infiltration are associated with stromal and epithelial prostatic hyperplasia in the nonobese diabetic mouse.
    Prostate. 2019;79:980-993.
    PubMed     Abstract available

  259. NICKKHOLGH B, Sittadjody S, Ordonez K, Rothberg MB, et al
    Protein kinase D1 induces G1-phase cell-cycle arrest independent of Checkpoint kinases by phosphorylating Cell Division Cycle Phosphatase 25.
    Prostate. 2019;79:1053-1058.
    PubMed     Abstract available

    May 2019
  260. JIAO M, Qi M, Zhang F, Hu J, et al
    CUL4B regulates cancer stem-like traits of prostate cancer cells by targeting BMI1 via miR200b/c.
    Prostate. 2019 May 21. doi: 10.1002/pros.23835.
    PubMed     Abstract available

  261. WONG M, Bierman Y, Pettaway C, Kittles R, et al
    Comparative analysis of p16 expression among African American and European American prostate cancer patients.
    Prostate. 2019 May 21. doi: 10.1002/pros.23833.
    PubMed     Abstract available

  262. WU X, Scott H, Carlsson SV, Sjoberg DD, et al
    Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy.
    Prostate. 2019 May 18. doi: 10.1002/pros.23817.
    PubMed     Abstract available

  263. SUN Y, Ai JZ, Jin X, Liu LR, et al
    IL-8 protects prostate cancer cells from GSK-3beta-induced oxidative stress by activating the mTOR signaling pathway.
    Prostate. 2019 May 18. doi: 10.1002/pros.23836.
    PubMed     Abstract available

  264. BLACKBURN J, Vecchiarelli S, Heyer EE, Patrick SM, et al
    TMPRSS2-ERG fusions linked to prostate cancer racial health disparities: A focus on Africa.
    Prostate. 2019 May 15. doi: 10.1002/pros.23823.
    PubMed     Abstract available

  265. HERNANDEZ-LLODRA S, Segales L, Safont A, Juanpere N, et al
    SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
    Prostate. 2019 May 15. doi: 10.1002/pros.23830.
    PubMed     Abstract available

  266. RAMAKRISHNAN S, Steck SE, Arab L, Zhang H, et al
    Association among plasma 1,25(OH)2 D, ratio of 1,25(OH)2 D to 25(OH)D, and prostate cancer aggressiveness.
    Prostate. 2019 May 11. doi: 10.1002/pros.23824.
    PubMed     Abstract available

  267. HAN IH, Kim JH, Jang KS, Ryu JS, et al
    Inflammatory mediators of prostate epithelial cells stimulated with Trichomonas vaginalis promote proliferative and invasive properties of prostate cancer cells.
    Prostate. 2019 May 2. doi: 10.1002/pros.23826.
    PubMed     Abstract available

  268. KRYVENKO ON, Wang Y, Sadasivan S, Gupta NS, et al
    Potential effect of anti-inflammatory drug use on PSA kinetics and subsequent prostate cancer diagnosis: Risk stratification in black and white men with benign prostate biopsy.
    Prostate. 2019 May 2. doi: 10.1002/pros.23820.
    PubMed     Abstract available

  269. MCNAMARA MA, Oyekunle T, Chin BB, Oldan J, et al
    Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
    Prostate. 2019 May 2. doi: 10.1002/pros.23822.
    PubMed     Abstract available

  270. KURUL NO, Ates F, Yilmaz I, Narli G, et al
    The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease.
    Prostate. 2019 May 2. doi: 10.1002/pros.23825.
    PubMed     Abstract available

  271. Re: Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer. The Prostate. 2019;1-7.
    Prostate. 2019;79:813-814.

  272. Koochekpour S, Maresh GA, Katner A, Parker-Johnson K, Lee TJ, Hebert FE, Kao YS, Skinner J, Rayford W. Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA. Prostate 2004;60(2):141-152.
    Prostate. 2019;79:815.

  273. PADDA RS, Deng FK, Brett SI, Biggs CN, et al
    Nanoscale flow cytometry to distinguish subpopulations of prostate extracellular vesicles in patient plasma.
    Prostate. 2019;79:592-603.
    PubMed     Abstract available

  274. SIMONS BW, Turtle NF, Ulmert DH, Abou DS, et al
    PSMA expression in the Hi-Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool.
    Prostate. 2019;79:678-685.
    PubMed     Abstract available

  275. KOLEVA M, Dikov D, Belovejdov V, Sarafian V, et al
    Expression of MUC1 in eosinophilic metaplasia of the prostate.
    Prostate. 2019;79:622-627.
    PubMed     Abstract available

    April 2019
  276. DUIJVESZ D, Rodriguez-Blanco G, Hoogland AM, Verhoef EI, et al
    Differential tissue expression of extracellular vesicle-derived proteins in prostate cancer.
    Prostate. 2019 Apr 24. doi: 10.1002/pros.23813.
    PubMed     Abstract available

  277. XIANG P, Jin S, Yang Y, Sheng J, et al
    Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling.
    Prostate. 2019 Apr 24. doi: 10.1002/pros.23810.
    PubMed     Abstract available

  278. MOLL JM, Kumagai J, van Royen ME, Teubel WJ, et al
    A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.
    Prostate. 2019 Apr 24. doi: 10.1002/pros.23799.
    PubMed     Abstract available

  279. YILMAZ B, Turkay R, Colakoglu Y, Baytekin HF, et al
    Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.
    Prostate. 2019 Apr 23. doi: 10.1002/pros.23812.
    PubMed     Abstract available

  280. VIDOTTO T, Saggioro FP, Jamaspishvili T, Chesca DL, et al
    PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
    Prostate. 2019 Apr 18. doi: 10.1002/pros.23808.
    PubMed     Abstract available

  281. HONDA M, Kimura T, Kamata Y, Tashiro K, et al
    Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
    Prostate. 2019 Apr 18. doi: 10.1002/pros.23816.
    PubMed     Abstract available

  282. KIM S, Zhang Y, Tang S, Qin C, et al
    Optimizing live-animal bioluminescence imaging prediction of tumor burden in human prostate cancer xenograft models in SCID-NSG mice.
    Prostate. 2019 Apr 8. doi: 10.1002/pros.23802.
    PubMed     Abstract available

  283. MCDONALD AC, Vira M, Walter V, Shen J, et al
    Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy.
    Prostate. 2019 Apr 8. doi: 10.1002/pros.23803.
    PubMed     Abstract available

  284. GANG X, Xuan L, Zhao X, Lv Y, et al
    Speckle-type POZ protein suppresses lipid accumulation and prostate cancer growth by stabilizing fatty acid synthase.
    Prostate. 2019 Apr 7. doi: 10.1002/pros.23793.
    PubMed     Abstract available

    March 2019
  285. KRISTIANSEN A, Bergstrom R, Delahunt B, Samaratunga H, et al
    Somatic alterations detected in diagnostic prostate biopsies provide an inadequate representation of multifocal prostate cancer.
    Prostate. 2019 Mar 25. doi: 10.1002/pros.23797.
    PubMed     Abstract available

  286. KRZYZANOWSKA A, Don-Doncow N, Marginean FE, Gaber A, et al
    Expression of tSTAT3, pSTAT3(727) , and pSTAT3 (705) in the epithelial cells of hormone-naive prostate cancer.
    Prostate. 2019 Mar 24. doi: 10.1002/pros.23787.
    PubMed     Abstract available

  287. MILLIRON BJ, Bruneau M, Obeid E, Gross L, et al
    Diet assessment among men undergoing genetic counseling and genetic testing for inherited prostate cancer: Exploring a teachable moment to support diet intervention.
    Prostate. 2019 Mar 24. doi: 10.1002/pros.23783.
    PubMed     Abstract available

  288. OH M, Alkhushaym N, Fallatah S, Althaghfi A, et al
    The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
    Prostate. 2019 Mar 22. doi: 10.1002/pros.23795.
    PubMed     Abstract available

  289. YUAN L, Huang X, Zhou K, Zhu X, et al
    Sea cucumber extract TBL-12 inhibits the proliferation, migration, and invasion of human prostate cancer cells through the p38 mitogen-activated protein kinase and intrinsic caspase apoptosis pathway.
    Prostate. 2019 Mar 19. doi: 10.1002/pros.23788.
    PubMed     Abstract available

  290. JAGARLAMUDI KK, Zupan M, Kumer K, Fabjan T, et al
    The combination of AroCell TK 210 ELISA with Prostate Health Index or prostate-specific antigen density can improve the ability to differentiate prostate cancer from noncancerous conditions.
    Prostate. 2019 Mar 19. doi: 10.1002/pros.23791.
    PubMed     Abstract available

  291. SCHWEIZER MT, Gulati R, Beightol M, Konnick EQ, et al
    Clinical determinants for successful circulating tumor DNA analysis in prostate cancer.
    Prostate. 2019 Mar 13. doi: 10.1002/pros.23778.
    PubMed     Abstract available

  292. WANG X, Qi M, Zhang J, Sun X, et al
    Differential response to neoadjuvant hormonal therapy in prostate cancer: Predictive morphological parameters and molecular markers.
    Prostate. 2019 Mar 2. doi: 10.1002/pros.23777.
    PubMed     Abstract available

  293. ZHANG W, van Weerden WM, de Ridder CMA, Erkens-Schulze S, et al
    Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response.
    Prostate. 2019;79:390-402.
    PubMed     Abstract available

  294. PENG W, Guo L, Tang R, Liu X, et al
    Sox7 negatively regulates prostate-specific membrane antigen (PSMA) expression through PSMA-enhancer.
    Prostate. 2019;79:370-378.
    PubMed     Abstract available

    February 2019
  295. LEE SI, Roney MSI, Park JH, Baek JY, et al
    Dopamine receptor antagonists induce differentiation of PC-3 human prostate cancer cell-derived cancer stem cell-like cells.
    Prostate. 2019 Feb 28. doi: 10.1002/pros.23779.
    PubMed     Abstract available

  296. XUE YN, Yu BB, Liu YN, Guo R, et al
    Zinc promotes prostate cancer cell chemosensitivity to paclitaxel by inhibiting epithelial-mesenchymal transition and inducing apoptosis.
    Prostate. 2019 Feb 3. doi: 10.1002/pros.23772.
    PubMed     Abstract available

  297. XU Y, Song Q, Pascal LE, Zhong M, et al
    DHX15 is up-regulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations.
    Prostate. 2019 Feb 3. doi: 10.1002/pros.23773.
    PubMed     Abstract available

  298. YU SH, Maynard JP, Vaghasia AM, De Marzo AM, et al
    A role for paracrine interleukin-6 signaling in the tumor microenvironment in prostate tumor growth.
    Prostate. 2019;79:215-222.
    PubMed     Abstract available

  299. KELLY NP, Flood HD, Hoey DA, Kiely PA, et al
    Direct mechanical characterization of prostate tissue-a systematic review.
    Prostate. 2019;79:115-125.
    PubMed     Abstract available

  300. MINNER S, Lutz J, Hube-Magg C, Kluth M, et al
    Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.
    Prostate. 2019;79:302-311.
    PubMed     Abstract available

  301. SASAKI T, Franco OE, Ohishi K, Filipovich Y, et al
    Tyrosine kinase inhibitor therapy prescribed for non-urologic diseases can modify PSA titers in urology patients.
    Prostate. 2019;79:259-264.
    PubMed     Abstract available

  302. MEUNIER ME, Neuzillet Y, Raynaud JP, Radulescu C, et al
    Sex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial).
    Prostate. 2019;79:272-280.
    PubMed     Abstract available

    January 2019
  303. GAUR S, Gross ME, Liao CP, Qian B, et al
    Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
    Prostate. 2019 Jan 28. doi: 10.1002/pros.23774.
    PubMed     Abstract available

  304. CHOI YH, Han DH, Kim SW, Kim MJ, et al
    A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation.
    Prostate. 2019 Jan 22. doi: 10.1002/pros.23766.
    PubMed     Abstract available

  305. GHINEA N, Robin B, Pichon C, Leclere R, et al
    Vasa nervorum angiogenesis in prostate cancer with perineural invasion.
    Prostate. 2019 Jan 20. doi: 10.1002/pros.23771.
    PubMed     Abstract available

  306. LI C, He C, Xu Y, Xu H, et al
    Alternol eliminates excessive ATP production by disturbing Krebs cycle in prostate cancer.
    Prostate. 2019 Jan 20. doi: 10.1002/pros.23767.
    PubMed     Abstract available

  307. PETRYLAK DP, Kantoff P, Vogelzang NJ, Mega A, et al
    Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
    Prostate. 2019 Jan 20. doi: 10.1002/pros.23765.
    PubMed     Abstract available

  308. JOENTAUSTA RM, Rannikko A, Murtola TJ
    Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort.
    Prostate. 2019 Jan 16. doi: 10.1002/pros.23768.
    PubMed     Abstract available

  309. LIU Y, Wu X, Jiang H
    Combined maternal and post-weaning high fat diet inhibits male offspring's prostate cancer tumorigenesis in transgenic adenocarcinoma of mouse prostate model.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23760.
    PubMed     Abstract available

  310. FAN L, Yang Y, Chi C, Ma X, et al
    Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23762.
    PubMed     Abstract available

  311. PAPANICOLAU-SENGOS A, Yang Y, Pabla S, Lenzo FL, et al
    Identification of targets for prostate cancer immunotherapy.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23756.
    PubMed     Abstract available

  312. HATANAKA Y, de Velasco MA, Oki T, Shimizu N, et al
    HOXA10 expression profiling in prostate cancer.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23761.
    PubMed     Abstract available

  313. ZHAO M, Qi M, Li X, Hu J, et al
    CUL4B/miR-33b/C-MYC axis promotes prostate cancer progression.
    Prostate. 2019 Jan 4. doi: 10.1002/pros.23754.
    PubMed     Abstract available

  314. BROADFIELD LA, Marcinko K, Tsakiridis E, Zacharidis PG, et al
    Salicylate enhances the response of prostate cancer to radiotherapy.
    Prostate. 2019 Jan 4. doi: 10.1002/pros.23755.
    PubMed     Abstract available

    December 2018
  315. TSUMURA H, Ishiyama H, Tabata KI, Sekiguchi A, et al
    Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study.
    Prostate. 2018 Dec 26. doi: 10.1002/pros.23757.
    PubMed     Abstract available

  316. MATEUS PAM, Kido LA, Silva RS, Cagnon VHA, et al
    Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
    Prostate. 2018 Dec 25. doi: 10.1002/pros.23758.
    PubMed     Abstract available

  317. DONADIO JLS, Liu L, Freeman VL, Ekoue DN, et al
    Interaction of NKX3.1 and SELENOP genotype with prostate cancer recurrence.
    Prostate. 2018 Dec 23. doi: 10.1002/pros.23752.
    PubMed     Abstract available

  318. IWAMOTO H, Izumi K, Natsagdorj A, Naito R, et al
    Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells.
    Prostate. 2018 Dec 19. doi: 10.1002/pros.23753.
    PubMed     Abstract available

  319. JOHNG D, Torga G, Ewing CM, Jin K, et al
    HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer.
    Prostate. 2018 Dec 17. doi: 10.1002/pros.23747.
    PubMed     Abstract available

  320. BARBAUD M, Frindel M, Ferrer L, Le Thiec M, et al
    68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
    Prostate. 2018 Dec 14. doi: 10.1002/pros.23751.
    PubMed     Abstract available

  321. ADAMO H, Hammarsten P, Hagglof C, Dahl Scherdin T, et al
    Prostate cancer induces C/EBPbeta expression in surrounding epithelial cells which relates to tumor aggressiveness and patient outcome.
    Prostate. 2018 Dec 11. doi: 10.1002/pros.23749.
    PubMed     Abstract available

  322. ZEDAN AH, Hansen TF, Assenholt J, Madsen JS, et al
    Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy.
    Prostate. 2018 Dec 9. doi: 10.1002/pros.23748.
    PubMed     Abstract available

    November 2018
  323. ERLANDSSON A, Carlsson J, Lundholm M, Falt A, et al
    M2 macrophages and regulatory T cells in lethal prostate cancer.
    Prostate. 2018 Nov 30. doi: 10.1002/pros.23742.
    PubMed     Abstract available

  324. MAJERA D, Skrott Z, Bouchal J, Bartkova J, et al
    Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.
    Prostate. 2018 Nov 29. doi: 10.1002/pros.23741.
    PubMed     Abstract available

  325. KRUEGER TE, Thorek DLJ, Meeker AK, Isaacs JT, et al
    Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?
    Prostate. 2018 Nov 28. doi: 10.1002/pros.23738.
    PubMed     Abstract available

  326. COHEN M, Amir S, Golan M, Ben-Neriah Y, et al
    beta-TrCP upregulates HIF-1 in prostate cancer cells.
    Prostate. 2018 Nov 28. doi: 10.1002/pros.23746.
    PubMed     Abstract available

  327. MIYAKE M, Tanaka N, Hori S, Ohnishi S, et al
    Dual benefit of supplementary oral 5-aminolevulinic acid to pelvic radiotherapy in a syngenic prostate cancer model.
    Prostate. 2018 Nov 18. doi: 10.1002/pros.23740.
    PubMed     Abstract available

  328. GIRI VN, Hegarty SE, Hyatt C, O'Leary E, et al
    Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
    Prostate. 2018 Nov 18. doi: 10.1002/pros.23739.
    PubMed     Abstract available

  329. ALANEE S, Holland B, Clemons J, Dynda D, et al
    Death due to sepsis in patients diagnosed with prostate cancer.
    Prostate. 2018 Nov 18. doi: 10.1002/pros.23735.
    PubMed     Abstract available

  330. GIULIANELLI R, Nardoni S, Bruzzese D, Falavolti C, et al
    Urotensin II receptor expression in prostate cancer patients: A new possible marker.
    Prostate. 2018 Nov 8. doi: 10.1002/pros.23734.
    PubMed     Abstract available

    October 2018
  331. MIYAHIRA AK, Den RB, Carlo MI, de Leeuw R, et al
    Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting.
    Prostate. 2018 Oct 31. doi: 10.1002/pros.23729.
    PubMed     Abstract available

  332. LAVOIE JM, Zou K, Khalaf D, Eigl BJ, et al
    Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis.
    Prostate. 2018 Oct 28. doi: 10.1002/pros.23733.
    PubMed     Abstract available

  333. SUER I, Guzel E, Karatas OF, Creighton CJ, et al
    MicroRNAs as prognostic markers in prostate cancer.
    Prostate. 2018 Oct 21. doi: 10.1002/pros.23731.
    PubMed     Abstract available

  334. ESKRA JN, Schlicht MJ, Bosland MC
    Lack of combination effects of soy isoflavones and taxane chemotherapy of castration-resistant prostate cancer.
    Prostate. 2018 Oct 21. doi: 10.1002/pros.23727.
    PubMed     Abstract available

  335. KRANZBUHLER B, Salemi S, Mortezavi A, Sulser T, et al
    Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Prostate. 2018 Oct 21. doi: 10.1002/pros.23725.
    PubMed     Abstract available

  336. SEKINO Y, Oue N, Mukai S, Shigematsu Y, et al
    Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.
    Prostate. 2018 Oct 16. doi: 10.1002/pros.23728.
    PubMed     Abstract available

  337. ERYILMAZ IE, Aytac Vuruskan B, Kaygisiz O, Egeli U, et al
    RNA-based markers in biopsy cores with atypical small acinar proliferation: Predictive effect of T2E fusion positivity and MMP-2 upregulation for a subsequent prostate cancer diagnosis.
    Prostate. 2018 Oct 7. doi: 10.1002/pros.23724.
    PubMed     Abstract available

  338. WADOSKY KM, Shourideh M, Goodrich DW, Koochekpour S, et al
    Riluzole induces AR degradation via endoplasmic reticulum stress pathway in androgen-dependent and castration-resistant prostate cancer cells.
    Prostate. 2018 Oct 2. doi: 10.1002/pros.23719.
    PubMed     Abstract available

    September 2018
  339. JAIN S, Dash P, Minz AP, Satpathi S, et al
    Lipopolysaccharide (LPS) enhances prostate cancer metastasis potentially through NF-kappaB activation and recurrent dexamethasone administration fails to suppress it in vivo.
    Prostate. 2018 Sep 27. doi: 10.1002/pros.23722.
    PubMed     Abstract available

  340. WANG J, Lu Z, Wu C, Li Y, et al
    Evaluation of the anticancer and anti-metastasis effects of novel synthetic sodium channel blockers in prostate cancer cells in vitro and in vivo.
    Prostate. 2018 Sep 21. doi: 10.1002/pros.23711.
    PubMed     Abstract available

  341. ROBERTO D, Klotz LH, Venkateswaran V
    Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner.
    Prostate. 2018 Sep 21. doi: 10.1002/pros.23720.
    PubMed     Abstract available

  342. LIU J, Ding D, Jiang Z, Du T, et al
    Long non-coding RNA CCAT1/miR-148a/PKCzeta prevents cell migration of prostate cancer by altering macrophage polarization.
    Prostate. 2018 Sep 16. doi: 10.1002/pros.23716.
    PubMed     Abstract available

  343. GHORBANMEHR N, Gharbi S, Korsching E, Tavallaei M, et al
    miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer.
    Prostate. 2018 Sep 7. doi: 10.1002/pros.23714.
    PubMed     Abstract available

  344. CHEN Z, Jiang Q, Zhu P, Chen Y, et al
    NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
    Prostate. 2018 Sep 3. doi: 10.1002/pros.23709.
    PubMed     Abstract available

  345. DUGUE PA, Dowty JG, Joo JE, Wong EM, et al
    Heritable methylation marks associated with breast and prostate cancer risk.
    Prostate. 2018;78:962-969.
    PubMed     Abstract available

  346. VAN DUIJN PW, Marques RB, Ziel-van der Made ACJ, van Zoggel HJAA, et al
    Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.
    Prostate. 2018;78:1013-1023.
    PubMed     Abstract available

    August 2018
  347. LI Y, Zhang Q, Lovnicki J, Chen R, et al
    SRRM4 gene expression correlates with neuroendocrine prostate cancer.
    Prostate. 2018 Aug 28. doi: 10.1002/pros.23715.
    PubMed     Abstract available

  348. PALLER C, Pu H, Begemann DE, Wade CA, et al
    TGF-beta receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer.
    Prostate. 2018 Aug 28. doi: 10.1002/pros.23708.
    PubMed     Abstract available

  349. XIE W, Stopsack KH, Drouin SJ, Fu H, et al
    Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival.
    Prostate. 2018 Aug 23. doi: 10.1002/pros.23712.
    PubMed     Abstract available

  350. TOMMASI S, Pilato B, Carella C, Lasorella A, et al
    Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
    Prostate. 2018 Aug 23. doi: 10.1002/pros.23710.
    PubMed     Abstract available

  351. ALANEE S, El-Zawahry A, Dynda D, Dabaja A, et al
    A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis.
    Prostate. 2018 Aug 16. doi: 10.1002/pros.23713.
    PubMed     Abstract available

  352. WEISSENRIEDER JS, Reilly JE, Neighbors JD, Hohl RJ, et al
    Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models.
    Prostate. 2018 Aug 14. doi: 10.1002/pros.23707.
    PubMed     Abstract available

  353. HUANG W, Su X, Yan W, Kong Z, et al
    Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer.
    Prostate. 2018 Aug 13. doi: 10.1002/pros.23700.
    PubMed     Abstract available

  354. CUI F, Hu J, Ning S, Tan J, et al
    Overexpression of MCM10 promotes cell proliferation and predicts poor prognosis in prostate cancer.
    Prostate. 2018 Aug 10. doi: 10.1002/pros.23703.
    PubMed     Abstract available

  355. GEVARIYA N, Besancon M, Robitaille K, Picard V, et al
    Omega-3 fatty acids decrease prostate cancer progression associated with an anti-tumor immune response in eugonadal and castrated mice.
    Prostate. 2018 Aug 2. doi: 10.1002/pros.23706.
    PubMed     Abstract available

  356. NAVONE NM, van Weerden WM, Vessella RL, Williams ED, et al
    Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
    Prostate. 2018 Aug 2. doi: 10.1002/pros.23701.
    PubMed     Abstract available

    July 2018
  357. CHAKRAVARTHI BVSK, Chandrashekar DS, Hodigere Balasubramanya SA, Robinson AD, et al
    Wnt receptor Frizzled 8 is a target of ERG in prostate cancer.
    Prostate. 2018 Jul 26. doi: 10.1002/pros.23704.
    PubMed     Abstract available

  358. KOIDE H, Kimura T, Inaba H, Sato S, et al
    Comparison of ERG and SPINK1 expression among incidental and metastatic prostate cancer in Japanese men.
    Prostate. 2018 Jul 26. doi: 10.1002/pros.23705.
    PubMed     Abstract available

  359. WU Y, Yu H, Zheng SL, Feng B, et al
    Germline mutations in PPFIBP2 are associated with lethal prostate cancer.
    Prostate. 2018 Jul 24. doi: 10.1002/pros.23697.
    PubMed     Abstract available

  360. LIU C, Zhu Y, Su H, Xu X, et al
    Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Prostate. 2018 Jul 19. doi: 10.1002/pros.23696.
    PubMed     Abstract available

  361. YAMAKAWA T, Waer C, Itakura K
    AT-rich interactive domain 5B regulates androgen receptor transcription in human prostate cancer cells.
    Prostate. 2018 Jul 19. doi: 10.1002/pros.23699.
    PubMed     Abstract available

  362. ROOT A, Ebhardt HA
    A two-drug combination simulation study for metastatic castrate resistant prostate cancer.
    Prostate. 2018 Jul 19. doi: 10.1002/pros.23694.
    PubMed     Abstract available

  363. YANG T, Jing Y, Dong J, Yu X, et al
    Regulation of ELL2 stability and polyubiquitination by EAF2 in prostate cancer cells.
    Prostate. 2018 Jul 15. doi: 10.1002/pros.23695.
    PubMed     Abstract available

  364. HE W, Li J
    Exendin-4 enhances radiation response of prostate cancer.
    Prostate. 2018 Jul 15. doi: 10.1002/pros.23687.
    PubMed     Abstract available

  365. LI D, Tian G, Wang J, Zhao LY, et al
    Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
    Prostate. 2018 Jul 15. doi: 10.1002/pros.23689.
    PubMed     Abstract available

  366. DORAI T, Shah A, Summers F, Mathew R, et al
    NRH:quinone oxidoreductase 2 (NQO2) and glutaminase (GLS) both play a role in large extracellular vesicles (LEV) formation in preclinical LNCaP-C4-2B prostate cancer model of progressive metastasis.
    Prostate. 2018 Jul 15. doi: 10.1002/pros.23693.
    PubMed     Abstract available

  367. TWEEDLE MF, Ding H, Drost WT, Dowell J, et al
    Development of an orthotopic canine prostate cancer model expressing human GRPr.
    Prostate. 2018 Jul 11. doi: 10.1002/pros.23686.
    PubMed     Abstract available

  368. LIM DM, Gulati R, Aleshin-Guendel S, Gawne A, et al
    Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival.
    Prostate. 2018 Jul 10. doi: 10.1002/pros.23666.
    PubMed     Abstract available

  369. ROGASCH JM, Cash H, Zschaeck S, Elezkurtaj S, et al
    Ga-68-PSMA PET/CT in treatment-naive patients with prostate cancer: Which clinical parameters and risk stratification systems best predict PSMA-positive metastases?
    Prostate. 2018 Jul 5. doi: 10.1002/pros.23685.
    PubMed     Abstract available

    June 2018
  370. ZHAO S, Leonardson A, Geybels MS, McDaniel AS, et al
    A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer.
    Prostate. 2018 Jun 28. doi: 10.1002/pros.23667.
    PubMed     Abstract available

  371. COOK SF, Fiandalo MV, Watt DS, Wu Y, et al
    Mathematical modeling of intracrine androgen metabolism in prostate cancer: Methodological aspects.
    Prostate. 2018 Jun 25. doi: 10.1002/pros.23665.
    PubMed     Abstract available

  372. HELFAND BT, Chen H, Fantus RJ, Conran CA, et al
    Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score.
    Prostate. 2018 Jun 19. doi: 10.1002/pros.23664.
    PubMed     Abstract available

  373. BARATA P, Emamekhoo H, Mendiratta P, Koshkin V, et al
    Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Prostate. 2018 Jun 7. doi: 10.1002/pros.23663.
    PubMed     Abstract available

  374. CHOUDHURY AD, Gray KP, Supko JG, Harshman LC, et al
    A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer.
    Prostate. 2018 Jun 7. doi: 10.1002/pros.23662.
    PubMed     Abstract available

  375. CHAKRAVARTHI BVSK, Goswami MT, Pathi SS, Dodson M, et al
    Expression and role of PAICS, a de novo purine biosynthetic gene in prostate cancer.
    Prostate. 2018;78:693-694.

  376. FURRER MA, Vilaseca A, Corradi RB, Boxler S, et al
    Repeat prostate biopsies prior to radical prostatectomy do not impact erectile function recovery and mid- to long-term continence.
    Prostate. 2018;78:631-636.
    PubMed     Abstract available

  377. THOMAS-JARDIN SE, Kanchwala MS, Jacob J, Merchant S, et al
    Identification of an IL-1-induced gene expression pattern in AR(+) PCa cells that mimics the molecular phenotype of AR(-) PCa cells.
    Prostate. 2018;78:595-606.
    PubMed     Abstract available

  378. OJALILL M, Rappu P, Siljamaki E, Taimen P, et al
    The composition of prostate core matrisome in vivo and in vitro unveiled by mass spectrometric analysis.
    Prostate. 2018;78:583-594.
    PubMed     Abstract available

    May 2018
  379. MIYAHIRA AK, Soule HR
    The 24th Annual Prostate Cancer Foundation scientific retreat report.
    Prostate. 2018 May 15. doi: 10.1002/pros.23651.
    PubMed     Abstract available

  380. AL SALEH HA, Haas-Neill S, Al-Hashimi A, Kapoor A, et al
    Thrombotic characteristics of extracellular vesicles derived from prostate cancer cells.
    Prostate. 2018 May 15. doi: 10.1002/pros.23653.
    PubMed     Abstract available

  381. JARVIS C, Nelius T, Martinez-Marin D, Sennoune SR, et al
    Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
    Prostate. 2018 May 10. doi: 10.1002/pros.23647.
    PubMed     Abstract available

  382. MUNOZ-MORENO L, Schally AV, Prieto JC, Carmena MJ, et al
    Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.
    Prostate. 2018 May 10. doi: 10.1002/pros.23648.
    PubMed     Abstract available

  383. TINAY I, Tan M, Gui B, Werner L, et al
    Functional roles and potential clinical application of miRNA-345-5p in prostate cancer.
    Prostate. 2018 May 10. doi: 10.1002/pros.23650.
    PubMed     Abstract available

  384. ALLOTT EH, Farnan L, Steck SE, Song L, et al
    Statin use, high cholesterol and prostate cancer progression; results from HCaP-NC.
    Prostate. 2018 May 1. doi: 10.1002/pros.23644.
    PubMed     Abstract available

  385. MIYAHIRA AK, Pienta KJ, Morris MJ, Bander NH, et al
    Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
    Prostate. 2018 May 1. doi: 10.1002/pros.23642.
    PubMed     Abstract available

  386. CAMPOLINA-SILVA GH, Maria BT, Mahecha GAB, Oliveira CA, et al
    Reduced vitamin D receptor (VDR) expression and plasma vitamin D levels are associated with aging-related prostate lesions.
    Prostate. 2018;78:532-546.
    PubMed     Abstract available

    April 2018
  387. ISHII K, Sasaki T, Iguchi K, Kajiwara S, et al
    Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
    Prostate. 2018 Apr 29. doi: 10.1002/pros.23643.
    PubMed     Abstract available

  388. FRANCINI E, Gray KP, Xie W, Shaw GK, et al
    Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
    Prostate. 2018 Apr 29. doi: 10.1002/pros.23645.
    PubMed     Abstract available

  389. BEYENE DA, Naab TJ, Kanarek NF, Apprey V, et al
    Differential expression of Annexin 2, SPINK1, and Hsp60 predict progression of prostate cancer through bifurcated WHO Gleason score categories in African American men.
    Prostate. 2018 Apr 22. doi: 10.1002/pros.23537.
    PubMed     Abstract available

  390. BAYAT H, Narouie B, Ziaee SM, Mowla SJ, et al
    Two long non-coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer.
    Prostate. 2018 Apr 19. doi: 10.1002/pros.23538.
    PubMed     Abstract available

  391. MILLER EA, Pinsky PF, Black A, Andriole GL, et al
    Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial.
    Prostate. 2018 Apr 17. doi: 10.1002/pros.23540.
    PubMed     Abstract available

  392. POMPE RS, Tilki D, Preisser F, Leyh-Bannurah SR, et al
    Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages.
    Prostate. 2018 Apr 16. doi: 10.1002/pros.23519.
    PubMed     Abstract available

  393. KOSTOVA MB, Brennen WN, Lopez D, Anthony L, et al
    PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones.
    Prostate. 2018 Apr 16. doi: 10.1002/pros.23539.
    PubMed     Abstract available

  394. GIRI VN, Obeid E, Hegarty SE, Gross L, et al
    Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling.
    Prostate. 2018 Apr 14. doi: 10.1002/pros.23535.
    PubMed     Abstract available

  395. MORI K, Kimura T, Ito K, Onuma H, et al
    Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
    Prostate. 2018 Apr 10. doi: 10.1002/pros.23534.
    PubMed     Abstract available

  396. BRATT O
    RE: Preissner F, et al. extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. The Prostate. 2018;1-7.
    Prostate. 2018 Apr 6. doi: 10.1002/pros.23520.

  397. KRANZBUHLER B, Salemi S, Umbricht CA, Muller C, et al
    Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells.
    Prostate. 2018 Apr 6. doi: 10.1002/pros.23522.
    PubMed     Abstract available

  398. PRENCIPE M, Fabre A, Murphy TB, Vargyas E, et al
    Role of serum response factor expression in prostate cancer biochemical recurrence.
    Prostate. 2018 Apr 2. doi: 10.1002/pros.23516.
    PubMed     Abstract available

  399. PREISSER F, Bandini M, Graefen M, Tilki D, et al
    Reply to the letter to the editor: RE: Preisser F, et al. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. The Prostate. 2018;1-7.
    Prostate. 2018 Apr 2. doi: 10.1002/pros.23521.

    March 2018
  400. GAO X, Mao YH, Xiao C, Li K, et al
    Calpain-2 triggers prostate cancer metastasis via enhancing CRMP4 promoter methylation through NF-kappaB/DNMT1 signaling pathway.
    Prostate. 2018 Mar 30. doi: 10.1002/pros.23512.
    PubMed     Abstract available

  401. BABCOOK MA, Akgul M, Margevicius S, MacLennan GT, et al
    Ser-486/491 phosphorylation and inhibition of AMPKalpha activity is positively associated with Gleason score, metastasis, and castration-resistance in prostate cancer: A retrospective clinical study.
    Prostate. 2018 Mar 26. doi: 10.1002/pros.23515.
    PubMed     Abstract available

  402. BRENNEN WN, Isaacs JT
    The what, when, and why of human prostate cancer xenografts.
    Prostate. 2018 Mar 24. doi: 10.1002/pros.23510.
    PubMed     Abstract available

  403. LINXWEILER J, Korbel C, Muller A, Hammer M, et al
    A novel mouse model of human prostate cancer to study intraprostatic tumor growth and the development of lymph node metastases.
    Prostate. 2018 Mar 24. doi: 10.1002/pros.23508.
    PubMed     Abstract available

  404. AKINBOYE ES, Rogers OC, Isaacs JT
    2-fluoro-5-maleimidobenzoic acid-linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer.
    Prostate. 2018 Mar 24. doi: 10.1002/pros.23494.
    PubMed     Abstract available

  405. CAMPOS C, Sotomayor P, Jerez D, Gonzalez J, et al
    Exercise and prostate cancer: From basic science to clinical applications.
    Prostate. 2018 Mar 23. doi: 10.1002/pros.23502.
    PubMed     Abstract available

  406. CHEN J, Oromendia C, Halpern JA, Ballman KV, et al
    National trends in management of localized prostate cancer: A population based analysis 2004-2013.
    Prostate. 2018 Mar 14. doi: 10.1002/pros.23496.
    PubMed     Abstract available

  407. WANG Y, Xu H, Si L, Li Q, et al
    MiR-206 inhibits proliferation and migration of prostate cancer cells by targeting CXCL11.
    Prostate. 2018 Mar 14. doi: 10.1002/pros.23468.
    PubMed     Abstract available

  408. DAVID SN, Arnold Egloff SA, Goyal R, Clark PE, et al
    MAGI2 is an independent predictor of biochemical recurrence in prostate cancer.
    Prostate. 2018 Mar 14. doi: 10.1002/pros.23506.
    PubMed     Abstract available

  409. CARLETON NM, Zhu G, Gorbounov M, Miller MC, et al
    PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.
    Prostate. 2018 Mar 9. doi: 10.1002/pros.23499.
    PubMed     Abstract available

  410. KEAM SP, Gulati T, Gamell C, Caramia F, et al
    Exploring the oncoproteomic response of human prostate cancer to therapeutic radiation using data-independent acquisition (DIA) mass spectrometry.
    Prostate. 2018 Mar 9. doi: 10.1002/pros.23500.
    PubMed     Abstract available

  411. HAYMAN J, Phillips R, Chen D, Perin J, et al
    Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.
    Prostate. 2018 Mar 9. doi: 10.1002/pros.23507.
    PubMed     Abstract available

  412. WU Y, Yu H, Zheng SL, Na R, et al
    A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.
    Prostate. 2018 Mar 9. doi: 10.1002/pros.23505.
    PubMed     Abstract available

  413. OKEGAWA T, Ninomiya N, Masuda K, Nakamura Y, et al
    AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
    Prostate. 2018 Mar 5. doi: 10.1002/pros.23501.
    PubMed     Abstract available

  414. BERGSTROM SH, Jaremo H, Nilsson M, Adamo HH, et al
    Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness.
    Prostate. 2018;78:257-265.
    PubMed     Abstract available

    February 2018
  415. COPELAND BT, Pal SK, Bolton EC, Jones JO, et al
    The androgen receptor malignancy shift in prostate cancer.
    Prostate. 2018 Feb 23. doi: 10.1002/pros.23497.
    PubMed     Abstract available

  416. ITO K, Kimura T, Onuma H, Tabata R, et al
    Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
    Prostate. 2018 Feb 23. doi: 10.1002/pros.23493.
    PubMed     Abstract available

  417. MACCINI MA, Westfall NJ, Van Bokhoven A, Lucia MS, et al
    The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer.
    Prostate. 2018 Feb 19. doi: 10.1002/pros.23495.
    PubMed     Abstract available

  418. PREISSER F, Bandini M, Marchioni M, Nazzani S, et al
    Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
    Prostate. 2018 Feb 19. doi: 10.1002/pros.23491.
    PubMed     Abstract available

  419. SHOU J, Zhang Q, Wang S, Zhang D, et al
    The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study.
    Prostate. 2018 Feb 13. doi: 10.1002/pros.23492.
    PubMed     Abstract available

  420. DE LAERE B, Oeyen S, Van Oyen P, Ghysel C, et al
    Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
    Prostate. 2018 Feb 12. doi: 10.1002/pros.23488.
    PubMed     Abstract available

  421. SILVA JAF, Bruni-Cardoso A, Augusto TM, Damas-Souza DM, et al
    Macrophage roles in the clearance of apoptotic cells and control of inflammation in the prostate gland after castration.
    Prostate. 2018;78:95-103.
    PubMed     Abstract available

  422. RODRIGO MAM, Strmiska V, Horackova E, Buchtelova H, et al
    Sarcosine influences apoptosis and growth of prostate cells via cell-type specific regulation of distinct sets of genes.
    Prostate. 2018;78:104-112.
    PubMed     Abstract available

  423. PAZIEWSKA A, Mikula M, Dabrowska M, Kulecka M, et al
    Candidate diagnostic miRNAs that can detect cancer in prostate biopsy.
    Prostate. 2018;78:178-185.
    PubMed     Abstract available

    January 2018
  424. JIANG X, Huang Y, Liang X, Jiang F, et al
    Metastatic prostate cancer-associated P62 inhibits autophagy flux and promotes epithelial to mesenchymal transition by sustaining the level of HDAC6.
    Prostate. 2018 Jan 31. doi: 10.1002/pros.23487.
    PubMed     Abstract available

  425. KARLSSON T, Sundar R, Widmark A, Landstrom M, et al
    Osteoblast-derived factors promote metastatic potential in human prostate cancer cells, in part via non-canonical transforming growth factor beta (TGFbeta) signaling.
    Prostate. 2018 Jan 31. doi: 10.1002/pros.23489.
    PubMed     Abstract available

  426. MCDONALD AC, Vira M, Shen J, Sanda M, et al
    Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer.
    Prostate. 2018 Jan 31. doi: 10.1002/pros.23485.
    PubMed     Abstract available

  427. WANG L, Kim D, Wise JTF, Shi X, et al
    p62 as a therapeutic target for inhibition of autophagy in prostate cancer.
    Prostate. 2018 Jan 25. doi: 10.1002/pros.23483.
    PubMed     Abstract available

  428. WURNSCHIMMEL C, Grande P, Moschini M, Ferrari M, et al
    Accuracy of standardized 12-core template biopsies versus non-standardized biopsies for detection of Epstein Grade 5 prostate cancer regarding the histology of the prostatectomy specimen.
    Prostate. 2018 Jan 25. doi: 10.1002/pros.23480.
    PubMed     Abstract available

  429. ISAACSSON VELHO P, Silberstein JL, Markowski MC, Luo J, et al
    Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
    Prostate. 2018 Jan 25. doi: 10.1002/pros.23484.
    PubMed     Abstract available

  430. MIKI J, Yanagisawa T, Tsuzuki S, Mori K, et al
    Anatomical localization and clinical impact of sentinel lymph nodes based on patterns of pelvic lymphatic drainage in clinically localized prostate cancer.
    Prostate. 2018 Jan 25. doi: 10.1002/pros.23486.
    PubMed     Abstract available

  431. DU Z, Lubmawa A, Gundell S, Wan P, et al
    Genetic risk of prostate cancer in ugandan men.
    Prostate. 2018 Jan 21. doi: 10.1002/pros.23481.
    PubMed     Abstract available

  432. BEEBE-DIMMER JL, Zuhlke KA, Johnson AM, Liesman D, et al
    Rare germline mutations in African American men diagnosed with early-onset prostate cancer.
    Prostate. 2018 Jan 21. doi: 10.1002/pros.23464.
    PubMed     Abstract available

  433. HUANG H, Wang Q, Du T, Lin C, et al
    Matrine inhibits the progression of prostate cancer by promoting expression of GADD45B.
    Prostate. 2018 Jan 21. doi: 10.1002/pros.23469.
    PubMed     Abstract available

  434. SU Z, Zhang M, Xu M, Li X, et al
    MicroRNA181c inhibits prostate cancer cell growth and invasion by targeting multiple ERK signaling pathway components.
    Prostate. 2018 Jan 16. doi: 10.1002/pros.23478.
    PubMed     Abstract available

  435. KIMBROUGH-ALLAH MN, Millena AC, Khan SA
    Differential role of PTEN in transforming growth factor beta (TGF-beta) effects on proliferation and migration in prostate cancer cells.
    Prostate. 2018 Jan 16. doi: 10.1002/pros.23482.
    PubMed     Abstract available

  436. HENDRIKS RJ, Dijkstra S, Smit FP, Vandersmissen J, et al
    Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.
    Prostate. 2018 Jan 12. doi: 10.1002/pros.23477.
    PubMed     Abstract available

  437. XU L, Shen M, Chen X, Zhu R, et al
    Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Prostate. 2018 Jan 12. doi: 10.1002/pros.23479.
    PubMed     Abstract available

  438. AZUMA T
    Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: A retrospective study.
    Prostate. 2018 Jan 8. doi: 10.1002/pros.23470.

  439. ALBITAR M, Ma W, Lund L, Shahbaba B, et al
    Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancer.
    Prostate. 2018 Jan 8. doi: 10.1002/pros.23473.
    PubMed     Abstract available

  440. EKOUE DN, Ansong E, Liu L, Macias V, et al
    Correlations of SELENOF and SELENOP genotypes with serum selenium levels and prostate cancer.
    Prostate. 2018 Jan 5. doi: 10.1002/pros.23471.
    PubMed     Abstract available

  441. LIN HM, Lee BY, Castillo L, Spielman C, et al
    Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
    Prostate. 2018 Jan 5. doi: 10.1002/pros.23476.
    PubMed     Abstract available

  442. TYAGI P, Motley SS, Koyama T, Kashyap M, et al
    Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients.
    Prostate. 2018;78:17-24.
    PubMed     Abstract available

    December 2017
  443. VAN DER TOOM EE, Groot VP, Glavaris SA, Gemenetzis G, et al
    Analogous detection of circulating tumor cells using the AccuCyte((R)) -CyteFinder((R)) system and ISET system in patients with locally advanced and metastatic prostate cancer.
    Prostate. 2017 Dec 29. doi: 10.1002/pros.23474.
    PubMed     Abstract available

  444. FAN L, Wang R, Chi C, Cai W, et al
    Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
    Prostate. 2017 Dec 29. doi: 10.1002/pros.23465.
    PubMed     Abstract available

  445. MCLEOD AB, Stice JP, Wardell SE, Alley HM, et al
    Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
    Prostate. 2017 Dec 15. doi: 10.1002/pros.23467.
    PubMed     Abstract available

  446. ZUMSTEG ZS, Chen Z, Howard LE, Amling CL, et al
    Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH.
    Prostate. 2017;77:1592-1600.
    PubMed     Abstract available

  447. ZHOU CK, Stanczyk FZ, Hafi M, Veneroso CC, et al
    Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers.
    Prostate. 2017;77:1573-1582.
    PubMed     Abstract available

  448. BAUER SR, Van Blarigan EL, Stampfer MJ, Chan JM, et al
    Mediterranean diet after prostate cancer diagnosis and urinary and sexual functioning: The health professionals follow-up study.
    Prostate. 2017 Dec 1. doi: 10.1002/pros.23457.
    PubMed     Abstract available

  449. ANDO T, Nishiyama T, Takizawa I, Miyashiro Y, et al
    A carbon 21 steroidal metabolite from progestin, 20beta-hydroxy-5alpha-dihydroprogesterone, stimulates the androgen receptor in prostate cancer cells.
    Prostate. 2017 Dec 1. doi: 10.1002/pros.23460.
    PubMed     Abstract available

  450. FIANDALO MV, Wilton JH, Mantione KM, Wrzosek C, et al
    Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models.
    Prostate. 2017 Dec 1. doi: 10.1002/pros.23459.
    PubMed     Abstract available

    November 2017
  451. YAN G, Ru Y, Wu K, Yan F, et al
    GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.
    Prostate. 2017 Nov 27. doi: 10.1002/pros.23461.
    PubMed     Abstract available

  452. CHEN H, Ewing CM, Zheng S, Grindedaal EM, et al
    Genetic factors influencing prostate cancer risk in Norwegian men.
    Prostate. 2017 Nov 27. doi: 10.1002/pros.23453.
    PubMed     Abstract available

  453. JOSHU CE, Peskoe SB, Heaphy CM, Kenfield SA, et al
    Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells.
    Prostate. 2017 Nov 22. doi: 10.1002/pros.23462.
    PubMed     Abstract available

  454. TSUI KH, Chang YL, Feng TH, Hou CP, et al
    Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells.
    Prostate. 2017 Nov 22. doi: 10.1002/pros.23463.
    PubMed     Abstract available

  455. FACINA CH, Campos SGP, Goncalves BF, Goes RM, et al
    Long-term oral exposure to safe dose of bisphenol A in association with high-fat diet stimulate the prostatic lesions in a rodent model for prostate cancer.
    Prostate. 2017 Nov 17. doi: 10.1002/pros.23458.
    PubMed     Abstract available

  456. GHASHGHAEI M, Paliouras M, Heravi M, Bekerat H, et al
    Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
    Prostate. 2017 Nov 14. doi: 10.1002/pros.23445.
    PubMed     Abstract available

  457. KALSBEEK AMF, Chan EKF, Grogan J, Petersen DC, et al
    Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer.
    Prostate. 2017 Nov 14. doi: 10.1002/pros.23440.
    PubMed     Abstract available

  458. COARFA C, Florentin D, Putluri N, Ding Y, et al
    Influence of the neural microenvironment on prostate cancer.
    Prostate. 2017 Nov 13. doi: 10.1002/pros.23454.
    PubMed     Abstract available

  459. TAT D, Kenfield SA, Cowan JE, Broering JM, et al
    Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSURE).
    Prostate. 2017 Nov 6. doi: 10.1002/pros.23441.
    PubMed     Abstract available

  460. MARTINO T, Kudrolli TA, Kumar B, Salviano I, et al
    The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress.
    Prostate. 2017 Nov 6. doi: 10.1002/pros.23455.
    PubMed     Abstract available

  461. CHENG HH, Plets M, Li H, Higano CS, et al
    Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
    Prostate. 2017 Nov 6. doi: 10.1002/pros.23452.
    PubMed     Abstract available

  462. XIAO H, Wang J, Yan W, Cui Y, et al
    GLUT1 regulates cell glycolysis and proliferation in prostate cancer.
    Prostate. 2017 Nov 6. doi: 10.1002/pros.23448.
    PubMed     Abstract available

  463. SCHMIDKONZ C, Hollweg C, Beck M, Reinfelder J, et al
    99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.
    Prostate. 2017 Nov 6. doi: 10.1002/pros.23444.
    PubMed     Abstract available

  464. DAVIDSSON S, Andren O, Ohlson AL, Carlsson J, et al
    FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer.
    Prostate. 2017 Nov 6. doi: 10.1002/pros.23442.
    PubMed     Abstract available

    Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression.
    Prostate. 2017 Nov 2. doi: 10.1002/pros.23446.
    PubMed     Abstract available

  466. KATO M, Kimura K, Hirakawa A, Kobayashi Y, et al
    Prognostic parameter for high risk prostate cancer patients at initial presentation.
    Prostate. 2017 Nov 2. doi: 10.1002/pros.23438.
    PubMed     Abstract available

  467. TJON-KON-FAT LA, Lundholm M, Schroder M, Wurdinger T, et al
    Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients.
    Prostate. 2017 Nov 2. doi: 10.1002/pros.23443.
    PubMed     Abstract available

  468. NESBITT H, Worthington J, Errington RJ, Patterson LH, et al
    The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.
    Prostate. 2017;77:1539-1547.
    PubMed     Abstract available

    October 2017
  469. STARK TW, Hensley PJ, Spear A, Pu H, et al
    Predictive value of epithelial-mesenchymal-transition (EMT) signature and PARP-1 in prostate cancer radioresistance.
    Prostate. 2017 Oct 23. doi: 10.1002/pros.23435.
    PubMed     Abstract available

  470. WOODS-BURNHAM L, Basu A, Cajigas-Du Ross CK, Love A, et al
    The 22Rv1 prostate cancer cell line carries mixed genetic ancestry: Implications for prostate cancer health disparities research using pre-clinical models.
    Prostate. 2017 Oct 14. doi: 10.1002/pros.23437.
    PubMed     Abstract available

  471. LI E, Liu L, Li F, Luo L, et al
    PSCA promotes prostate cancer proliferation and cell-cycle progression by up-regulating c-Myc.
    Prostate. 2017 Oct 2. doi: 10.1002/pros.23432.
    PubMed     Abstract available

  472. ABEDINPOUR P, Baron VT, Chrastina A, Rondeau G, et al
    Plumbagin improves the efficacy of androgen deprivation therapy in prostate cancer: A pre-clinical study.
    Prostate. 2017 Oct 2. doi: 10.1002/pros.23428.
    PubMed     Abstract available

  473. SHI X, Peng Y, Du X, Liu H, et al
    Estradiol promotes epithelial-to-mesenchymal transition in human benign prostatic epithelial cells.
    Prostate. 2017;77:1424-1437.
    PubMed     Abstract available

  474. HAYASHI T, Fujita K, Nojima S, Hayashi Y, et al
    Peripheral blood monocyte count reflecting tumor-infiltrating macrophages is a predictive factor of adverse pathology in radical prostatectomy specimens.
    Prostate. 2017;77:1383-1388.
    PubMed     Abstract available

    September 2017
  475. BURDELSKI C, Shihada R, Hinsch A, Angerer A, et al
    High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer.
    Prostate. 2017 Sep 19. doi: 10.1002/pros.23431.
    PubMed     Abstract available

  476. MIYAHIRA AK, Cheng HH, Abida W, Ellis L, et al
    Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.
    Prostate. 2017 Sep 18. doi: 10.1002/pros.23424.
    PubMed     Abstract available

  477. TSUMURA H, Ishiyama H, Tabata KI, Katsumata H, et al
    Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapy.
    Prostate. 2017 Sep 14. doi: 10.1002/pros.23430.
    PubMed     Abstract available

  478. KANAYAMA M, Hayano T, Koebis M, Maeda T, et al
    Hyperactive mTOR induces neuroendocrine differentiation in prostate cancer cell with concurrent up-regulation of IRF1.
    Prostate. 2017 Sep 14. doi: 10.1002/pros.23425.
    PubMed     Abstract available

  479. PEDRAZA-AREVALO S, Hormaechea-Agulla D, Gomez-Gomez E, Requena MJ, et al
    Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer.
    Prostate. 2017 Sep 14. doi: 10.1002/pros.23426.
    PubMed     Abstract available

  480. STROMVALL K, Sundkvist K, Ljungberg B, Halin Bergstrom S, et al
    Reduced number of CD169+ macrophages in pre-metastatic regional lymph nodes is associated with subsequent metastatic disease in an animal model and with poor outcome in prostate cancer patients.
    Prostate. 2017 Sep 7. doi: 10.1002/pros.23407.
    PubMed     Abstract available

  481. YANG CS, Melhuish TA, Spencer A, Ni L, et al
    The protein kinase C super-family member PKN is regulated by mTOR and influences differentiation during prostate cancer progression.
    Prostate. 2017 Sep 6. doi: 10.1002/pros.23400.
    PubMed     Abstract available

  482. VINCENEUX A, Bruyere F, Haillot O, Charles T, et al
    Ductal adenocarcinoma of the prostate: Clinical and biological profiles.
    Prostate. 2017;77:1242-1250.
    PubMed     Abstract available

    August 2017
  483. GINSBURG KB, Elshafei A, Yu C, Jones JS, et al
    Avoidance of androgen deprivation therapy in radiorecurrent prostate cancer as a clinically meaningful endpoint for salvage cryoablation.
    Prostate. 2017 Aug 29. doi: 10.1002/pros.23406.
    PubMed     Abstract available

  484. SOEKMADJI C, Corcoran NM, Oleinikova I, Jovanovic L, et al
    Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.
    Prostate. 2017 Aug 29. doi: 10.1002/pros.23403.
    PubMed     Abstract available

  485. HENDRIKS RJ, van der Leest MMG, Dijkstra S, Barentsz JO, et al
    A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.
    Prostate. 2017 Aug 29. doi: 10.1002/pros.23401.
    PubMed     Abstract available

  486. SUH JH, Park JH, Lee C, Moon KC, et al
    Intrafocal heterogeneity of ERG protein expression and gene fusion pattern in prostate cancer.
    Prostate. 2017 Aug 28. doi: 10.1002/pros.23405.
    PubMed     Abstract available

  487. LIU L, Li E, Luo L, Zhao S, et al
    PSCA regulates IL-6 expression through p38/NF-kappaB signaling in prostate cancer.
    Prostate. 2017 Aug 28. doi: 10.1002/pros.23399.
    PubMed     Abstract available

  488. MIYATA Y, Nakamura Y, Yasuda T, Matsuo T, et al
    Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.
    Prostate. 2017 Aug 28. doi: 10.1002/pros.23402.
    PubMed     Abstract available

  489. DONG B, Fan L, Wang Y, Chi C, et al
    Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer.
    Prostate. 2017 Aug 14. doi: 10.1002/pros.23397.
    PubMed     Abstract available

  490. STRUSS WJ, Tan Z, Zachkani P, Moskalev I, et al
    Magnetically-actuated drug delivery device (MADDD) for minimally invasive treatment of prostate cancer: An in vivo animal pilot study.
    Prostate. 2017 Aug 8. doi: 10.1002/pros.23395.
    PubMed     Abstract available

  491. PALLER CJ, Cole AP, Partin AW, Carducci MA, et al
    Risk factors for metastatic prostate cancer: A sentinel event case series.
    Prostate. 2017 Aug 8. doi: 10.1002/pros.23396.
    PubMed     Abstract available

  492. VAN NESTE L, Groskopf J, Grizzle WE, Adams GW, et al
    Epigenetic risk score improves prostate cancer risk assessment.
    Prostate. 2017 Aug 1. doi: 10.1002/pros.23385.
    PubMed     Abstract available

  493. HARSHMAN LC, Werner L, Tripathi A, Wang X, et al
    The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer.
    Prostate. 2017 Aug 1. doi: 10.1002/pros.23390.
    PubMed     Abstract available

    July 2017
  494. FAN L, Wang X, Chi C, Wang Y, et al
    Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone.
    Prostate. 2017 Jul 28. doi: 10.1002/pros.23381.
    PubMed     Abstract available

  495. SUN G, Huang R, Zhang X, Shen P, et al
    The impact of multifocal perineural invasion on biochemical recurrence and timing of adjuvant androgen-deprivation therapy in high-risk prostate cancer following radical prostatectomy.
    Prostate. 2017 Jul 27. doi: 10.1002/pros.23388.
    PubMed     Abstract available

  496. SHARPE B, Alghezi DA, Cattermole C, Beresford M, et al
    A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells.
    Prostate. 2017 Jul 26. doi: 10.1002/pros.23391.
    PubMed     Abstract available

  497. LIN X, Chen Z, Gao P, Gao Z, et al
    TEX15: A DNA repair gene associated with prostate cancer risk in Han Chinese.
    Prostate. 2017 Jul 21. doi: 10.1002/pros.23387.
    PubMed     Abstract available

  498. AI J, Tai PWL, Lu Y, Li J, et al
    Characterization of adenoviral transduction profile in prostate cancer cells and normal prostate tissue.
    Prostate. 2017 Jul 20. doi: 10.1002/pros.23386.
    PubMed     Abstract available

  499. TODENHOFER T, Hennenlotter J, Keller G, Neumann T, et al
    Effect of radical prostatectomy on levels of cancer related epitopes in circulating macrophages of patients with clinically localized prostate cancer.
    Prostate. 2017 Jul 20. doi: 10.1002/pros.23384.
    PubMed     Abstract available

  500. BREEN KJ, O'Neill A, Murphy L, Fan Y, et al
    Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery.
    Prostate. 2017 Jul 20. doi: 10.1002/pros.23389.
    PubMed     Abstract available

  501. CHEN H, Na R, Packiam VT, Conran CA, et al
    Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.
    Prostate. 2017 Jul 2. doi: 10.1002/pros.23369.
    PubMed     Abstract available

  502. DE BARI B, Stish B, Ball MW, Habboush Y, et al
    Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study.
    Prostate. 2017;77:1160-1166.
    PubMed     Abstract available

  503. RODRIGUES TM, Mitre AI, da Silva LFF, Castilho LN, et al
    Periprostatic innervation: New issues based on segmental analysis of 10 human cadaver pelvic blocs.
    Prostate. 2017;77:1151-1159.
    PubMed     Abstract available

  504. BOKHORST LP, Roobol MJ, Bangma CH, van Leenders GJ, et al
    Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance.
    Prostate. 2017;77:1137-1143.
    PubMed     Abstract available

    June 2017
  505. LAWAL IO, Ankrah AO, Mokgoro NP, Vorster M, et al
    Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
    Prostate. 2017 Jun 26. doi: 10.1002/pros.23379.
    PubMed     Abstract available

  506. CRUMBAKER M, Gurney H
    Dose considerations for anti-cancer drugs in metastatic prostate cancer.
    Prostate. 2017 Jun 26. doi: 10.1002/pros.23378.
    PubMed     Abstract available

  507. HE C, Duan S, Dong L, Wang Y, et al
    Characterization of a novel p110beta-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.
    Prostate. 2017 Jun 20. doi: 10.1002/pros.23377.
    PubMed     Abstract available

  508. CAI B, Chen W, Pan Y, Chen H, et al
    Inhibition of microRNA-500 has anti-cancer effect through its conditional downstream target of TFPI in human prostate cancer.
    Prostate. 2017 Jun 20. doi: 10.1002/pros.23361.
    PubMed     Abstract available

  509. XU Y, Qin S, An T, Tang Y, et al
    MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
    Prostate. 2017 Jun 15. doi: 10.1002/pros.23376.
    PubMed     Abstract available

  510. ZHAO R, Sun F, Bei X, Wang X, et al
    Upregulation of the long non-coding RNA FALEC promotes proliferation and migration of prostate cancer cell lines and predicts prognosis of PCa patients.
    Prostate. 2017 Jun 6. doi: 10.1002/pros.23367.
    PubMed     Abstract available

  511. ARMSTRONG CM, Liu C, Lou W, Lombard AP, et al
    MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
    Prostate. 2017;77:1020-1028.
    PubMed     Abstract available

  512. GONZAGA ACR, Campolina-Silva GH, Werneck-Gomes H, Moura-Cordeiro JD, et al
    Profile of cell proliferation and apoptosis activated by the intrinsic and extrinsic pathways in the prostate of aging rats.
    Prostate. 2017;77:937-948.
    PubMed     Abstract available

  513. AJIBOYE AS, Esopi D, Yegnasubramanian S, Denmeade SR, et al
    Androgen Receptor Splice Variants Are Not Substrates of Nonsense-Mediated Decay.
    Prostate. 2017;77:829-837.
    PubMed     Abstract available

  514. KIDO LA, Montico F, Vendramini-Costa DB, Pilli RA, et al
    Goniothalamin and Celecoxib Effects During Aging: Targeting Pro-Inflammatory Mediators in Chemoprevention of Prostatic Disorders.
    Prostate. 2017;77:838-848.
    PubMed     Abstract available

  515. SHARIF A, Malhotra NR, Acosta AM, Kajdacsy-Balla AA, et al
    The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role?
    Prostate. 2017;77:824-828.
    PubMed     Abstract available

    May 2017
  516. MORI K, Kimura T, Onuma H, Kimura S, et al
    Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer.
    Prostate. 2017 May 30. doi: 10.1002/pros.23373.
    PubMed     Abstract available

  517. KIM Y, Park SE, Moon JW, Kim BM, et al
    Downregulation of androgen receptors by NaAsO2 via inhibition of AKT-NF-kappaB and HSP90 in castration resistant prostate cancer.
    Prostate. 2017 May 30. doi: 10.1002/pros.23370.
    PubMed     Abstract available

  518. NUNEZ BRAGAYRAC LA, Murekeyisoni C, Vacchio MJ, Attwood K, et al
    Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential.
    Prostate. 2017 May 26. doi: 10.1002/pros.23364.
    PubMed     Abstract available

  519. IRIZARRY-RAMIREZ M, Kittles RA, Wang X, Salgado-Montilla J, et al
    Genetic ancestry and prostate cancer susceptibility SNPs in Puerto Rican and African American men.
    Prostate. 2017 May 24. doi: 10.1002/pros.23368.
    PubMed     Abstract available

  520. MIYAHIRA AK, Soule HR
    The 23rd Annual Prostate Cancer Foundation Scientific Retreat report.
    Prostate. 2017 May 14. doi: 10.1002/pros.23366.
    PubMed     Abstract available

  521. NOVAKOVA Z, Foss CA, Copeland BT, Morath V, et al
    Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools.
    Prostate. 2017;77:749-764.
    PubMed     Abstract available

  522. HUANG H, Du T, Zhang Y, Lai Y, et al
    Elevation of SHARPIN Protein Levels in Prostate Adenocarcinomas Promotes Metastasis and Impairs Patient Survivals.
    Prostate. 2017;77:718-728.
    PubMed     Abstract available

  523. OLSON BM, Bradley ES, Sawicki T, Zhong W, et al
    Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD).
    Prostate. 2017;77:812-821.
    PubMed     Abstract available

  524. POMPE RS, Davis-Bondarenko H, Zaffuto E, Tian Z, et al
    Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment.
    Prostate. 2017;77:686-693.
    PubMed     Abstract available

  525. MELITI A, Sadimin E, Diolombi M, Khani F, et al
    Accuracy of Grading Gleason Score 7 Prostatic Adenocarcinoma on Needle Biopsy: Influence of Percent Pattern 4 and Other Histological Factors.
    Prostate. 2017;77:681-685.
    PubMed     Abstract available

  526. PIERCONTI F, Martini M, Cenci T, Petrone GL, et al
    SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.
    Prostate. 2017;77:597-603.
    PubMed     Abstract available

  527. HENNING JD, Karamchandani JM, Bonachea LA, Bunker CH, et al
    Elevated Serum PSA is Associated With Human Herpesvirus 8 Infection and Increased Circulating Cytokine Levels in Men From Tobago.
    Prostate. 2017;77:617-624.
    PubMed     Abstract available

  528. BRETT SI, Lucien F, Guo C, Williams KC, et al
    Immunoaffinity based methods are superior to kits for purification of prostate derived extracellular vesicles from plasma samples.
    Prostate. 2017;77:1335-1343.
    PubMed     Abstract available

    April 2017
  529. SCHALLY AV, Block NL, Rick FG
    Discovery of LHRH and development of LHRH analogs for prostate cancer treatment.
    Prostate. 2017 Apr 27. doi: 10.1002/pros.23360.
    PubMed     Abstract available

  530. CONTEDUCA V, Caffo O, Lolli C, Aieta M, et al
    Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.
    Prostate. 2017 Apr 20. doi: 10.1002/pros.23357.
    PubMed     Abstract available

  531. JIA L, Gui B, Zheng D, Decker KF, et al
    Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration.
    Prostate. 2017 Apr 19. doi: 10.1002/pros.23356.
    PubMed     Abstract available

  532. TANG B, Han CT, Gan HL, Zhang GM, et al
    Smoking increased the risk of prostate cancer with grade group >/= 4 and intraductal carcinoma in a prospective biopsy cohort.
    Prostate. 2017 Apr 19. doi: 10.1002/pros.23354.
    PubMed     Abstract available

  533. PELLEGRINI KL, Patil D, Douglas KJS, Lee G, et al
    Detection of prostate cancer-specific transcripts in extracellular vesicles isolated from post-DRE urine.
    Prostate. 2017 Apr 17. doi: 10.1002/pros.23355.
    PubMed     Abstract available

  534. DE CARVALHO TM, Heijnsdijk EAM, de Koning HJ
    When should active surveillance for prostate cancer stop if no progression is detected?
    Prostate. 2017 Apr 17. doi: 10.1002/pros.23352.
    PubMed     Abstract available

  535. GONCALVES BF, de Campos SG, Goes RM, Scarano WR, et al
    Dual action of high estradiol doses on MNU-induced prostate neoplasms in a rodent model with high serum testosterone: Protective effect and emergence of unstable epithelial microenvironment.
    Prostate. 2017 Apr 12. doi: 10.1002/pros.23353.
    PubMed     Abstract available

  536. NAKATA D, Koyama R, Nakayama K, Kitazawa S, et al
    Glycogen synthase kinase-3 inhibitors suppress the AR-V7-mediated transcription and selectively inhibit cell growth in AR-V7-positive prostate cancer cells.
    Prostate. 2017 Apr 10. doi: 10.1002/pros.23351.
    PubMed     Abstract available

  537. BEAUVAL JB, Cabarrou B, Gandaglia G, Patard PM, et al
    External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients.
    Prostate. 2017 Apr 2. doi: 10.1002/pros.23348.
    PubMed     Abstract available

    March 2017
  538. RUNDLE A, Wang Y, Sadasivan S, Chitale DA, et al
    Larger men have larger prostates: Detection bias in epidemiologic studies of obesity and prostate cancer risk.
    Prostate. 2017 Mar 27. doi: 10.1002/pros.23350.
    PubMed     Abstract available

  539. HABL G, Sauter K, Schiller K, Dewes S, et al
    68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment.
    Prostate. 2017 Mar 20. doi: 10.1002/pros.23347.
    PubMed     Abstract available

  540. WINCHESTER DA, Till C, Goodman PJ, Tangen CM, et al
    Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.
    Prostate. 2017 Mar 20. doi: 10.1002/pros.23346.
    PubMed     Abstract available

  541. TOLKACH Y, Eminaga O, Wotzel F, Huss S, et al
    Blind Biobanking of the Prostatectomy Specimen: Critical Evaluation of the Existing Techniques and Development of the New 4-Level Tissue Extraction Model With High Sampling Efficacy.
    Prostate. 2017;77:396-405.
    PubMed     Abstract available

    November 2016
  542. REGIS L, Planas J, Carles J, Maldonado X, et al
    Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone.
    Prostate. 2016 Nov 1. doi: 10.1002/pros.23256.
    PubMed     Abstract available

    July 2016
  543. GALHEIGO MR, Cruz AR, Cabral AS, Faria PR, et al
    Role of the TNF-alpha receptor type 1 on prostate carcinogenesis in knockout mice.
    Prostate. 2016;76:917-26.
    PubMed     Abstract available

  544. SARTOR O, Hoskin P, Coleman RE, Nilsson S, et al
    Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
    Prostate. 2016;76:905-16.
    PubMed     Abstract available

    June 2016
  545. GERRIN SJ, Sowalsky AG, Balk SP, Ye H, et al
    Mutation profiling indicates high grade prostatic intraepithelial neoplasia as distant precursors of adjacent invasive prostatic adenocarcinoma.
    Prostate. 2016 Jun 8. doi: 10.1002/pros.23212.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.